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Abstract 
 
Lower motor neurons of the peripheral nervous system are responsible for 
innervating skeletal muscle and controlling all voluntary movements of the 
body. Degeneration of motor neurons underlies conditions such as amyotrophic 
lateral sclerosis and spinal muscular atrophy. The identification of genetic 
factors that influence the form and function of the peripheral nervous system in 
vivo will be important for our understanding of the neuromuscular system in 
health and disease. Here, I have studied the effects of three different genes and 
their respective protein products on the peripheral nervous system: yellow 
fluorescent protein (YFP), apolipoprotein E (apoE) and Ercc1 (excision repair 
cross-complementing group 1). YFP has been used as a reporter protein in many 
fields of research, including as a powerful tool for visualising neurons in mice. It 
is used under the assumption that it is biologically inert. However, my findings 
have revealed that YFP expressed in neurons in mice is not inert: it induces a 
cell stress response at both the RNA and the protein level and alters the time 
course of dying-back neuropathy. ApoE is a lipid transport protein with three 
distinct isoforms in humans (apoE2, apoE3 and apoE4), which are known to 
differentially affect risk and outcome in a number of central nervous system 
disorders. However, the effects of different apoE isoforms on the peripheral 
nervous system have yet to be established. I have shown that apoE4 delays 
peripheral nerve regeneration and subsequent neuromuscular junction 
reinnervation compared to apoE3, in the absence of any effects on normal form 
or function, degeneration or developmental plasticity. Ercc1 protein is involved 
in several DNA repair systems. Ercc1∆/- mice have reduced levels of functional 
Ercc1 protein, which leads to a reduced life span and motor abnormalities, 
potentially due to a build of up DNA damage. Here I have shown that Ercc1∆/- 
mice also have increased abnormalities at the neuromuscular junction (an early 
pathological target in neurodegeneration) with age. These findings contribute 
significantly to our understanding of the influence of specific genes on the form 
and function of the peripheral nervous system in health and disease. 
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Chapter 1 – Introduction 
 
"To move things is all that mankind can do. For such, the sole executant is muscle – 
whether in whispering a syllable or felling a forest."  
C. S. Sherrington, English neurophysiologist (1857-1952) 
 
Every movement within the body is produced by patterns of muscle contraction, 
controlled by motor neurons from the brain and spinal cord. Understanding 
how this system works is therefore essential to understand both normal 
behaviour, and how it functions in disease.  
 
1.1 History of the nervous system 
It was Luigi Galvani who first proposed the idea that neural communication is 
due to bioelectricity, or animal electricity as he described it, in 1791, following 
his experiments on the interactions between electricity and muscular motion in 
frogs legs (Galvani, 1791; Lopez-Munoz and Alamo, 2009). This represented the 
beginning of modern neuroscience – before this the prevailing idea of how the 
nervous system functioned was based on an idea proposed by the classical 
Greek philosophers and modified by Galen (131-200), that inhaled air was 
transformed into ‘pneuma’ or ‘spiritus animalis’, which flowed through hollow 
nerves causing movement and sensation (Lopez-Munoz and Alamo, 2009).   
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Further breakthroughs in neuroscience came with the invention of the 
achromatic lens in 1824, which improved microscopes and allowed anatomists 
to see new levels of detail. The improvements in microscopy lead to the first 
descriptions of the structure of neurons by Valentin, (Lopez-Munoz and Alamo, 
2009; Valentin, 1836), and the idea that the nervous system could be composed 
of cells in the same way as other tissues in the body (Virchow, 1855), although 
the cells themselves remained unnamed until the end of the century, when the 
term ‘neuron’ was first used (Waldeyer, 1891). 
 
Whilst microscopy had improved, staining techniques were still not 
sophisticated enough to determine the cellular structure of the brain. This was a 
cause of much debate in the second half of the nineteenth century, with two 
opposing schools of thought: the reticularist theory and the neuron doctrine. 
The reticularist theory of the connectivity of neurons was proposed by Gerlach 
(Gerlach, 1871) and strongly supported by Camillo Golgi. It stated that the 
nervous system was made up of a ‘neural net’ with fused axons, along which a 
nervous impulse was propagated. In contrast, proponents of the neuron 
doctrine, such as Santiago Ramon y Cajal, believed that the nervous system was 
anatomically composed of individual cells that communicated with one another 
through points of contact (De Carlos and Borrell, 2007).  It was Cajal’s use of a 
histological technique discovered by Golgi, ‘la reazione nera’ (Golgi, 1873; De 
Carlos and Borrell, 2007), that allowed him to stain entire neurons and clearly 
see free terminals rather than anastomoses, which finally convinced people that 
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the neuron doctrine was the correct theory (Cajal, 1888a; Cajal, 1888b; Cajal, 
1889; De Carlos and Borrell, 2007).  
 
Once it had been established that neurons did not fuse, the major question was 
how electrical impulses were passed between cells. Sir Charles S. Sherrington 
studied the physiology of the synapse in the first half of the twentieth century, 
providing evidence for an integrated nervous system and excitatory and 
inhibitory synapses (a term which he coined from the Greek for connection; 
Lopez-Munoz and Alamo, 2009; Sherrington, 1906). However, it was not 
possible to visualise the gap between neurons until the invention of the electron 
microscope in 1954.  
 
In 1936 Dale and Loewi shared the Nobel Prize for their work on chemical 
neurotransmission. Dale used the peripheral nervous system (PNS) as a model 
to show that acetylcholine was functioning as a neurotransmitter, proving that 
synapses worked by chemical, and not electrical transmission (Dale and 
Feldberg, 1934; Tansey, 2006).  With the advent of electrophysiology the PNS, 
and the neuromuscular junction (NMJ) in particular, became instrumental in 
discovering how synapses functioned. The NMJ was useful because it is large 
and easily accessible, and relatively simple compared to synapses of the central 
nervous system (CNS).  
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1.2 Structure of the PNS 
The PNS is defined as all neurons lying out with the brain and spinal cord. This 
includes the autonomic nervous system, cranial nerves III to XII and the somatic 
nervous system, which innervates skeletal muscle causing movement.  
 
Muscles can be broadly divided into smooth muscle and striated muscle (due to 
it’s striped appearance under a microscope), which can be further subdivided 
into skeletal muscle and cardiac muscle. These groups of muscles differ in their 
functions and the parts of the nervous system that provide their innervation. 
Smooth muscle is innervated by the autonomic nervous system (ANS) and is 
found lining arteries and the digestive tract. Cardiac muscle is responsible for 
the heartbeat, and contracts rhythmically without the control of any innervation, 
although its rate can be changed by input from the ANS (Bear et al., 2001). The 
majority of muscle mass within the body is skeletal muscle, which is under the 
control of the somatic nervous system. This muscle is responsible for all 
voluntary movement: it moves bones, controls respiration and produces all 
facial expressions (Bear et al., 2001).  
 
The neurons responsible for innervating all skeletal muscle are lower motor 
neurons, which Sherrington called “the final common pathway” for the control 
of movement. The cell bodies of these are found in the ventral horn of the spinal 
cord and the brainstem (for motor neurons controlling muscles of the head and 
neck), from where bundles of axons will originate and pass out of the spinal 
cord through notches in between the vertebrae in a ventral root or via the 
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cranial nerves (Purves et al., 2004). In the periphery ventral roots will join dorsal 
roots (containing sensory fibres) and form mixed spinal nerves (Bear et al., 
2001). Lower motor neurons can be subdivided into two types: alpha motor 
neurons and gamma motor neurons. Gamma motor neurons adjust the level of 
tension in the intrafusal muscle fibres at either end of the muscle spindle, 
regulating the stretch reflex (Rossi-Durand, 2006). However, this thesis is 
primarily concerned with alpha motor neurons, which are directly responsible 
for the force of contraction produced by a muscle.  
 
At their distal end lower motor neurons communicate directly with skeletal 
muscle; these specialised junctions are NMJs, and are discussed below. An alpha 
motor neuron and all the muscle fibres it innervates is known as a motor unit 
(Sanes and Lichtman, 1999). All the motor neurons innervating a single muscle 
make up a motor neuron pool (Bear et al., 2001). 
 
An individual nerve is made up of many motor neuron axons bundled together, 
and contains several different cell types. The entire nerve is contained in a thick 
sheath of connective tissue, called the epineurium. The epineurium contains the 
blood vessels supplying the nerve, adipose tissue and bundles of axons held 
together in fascicles within a second connective tissue sheath – the perineurium 
(Sunderland, 1965). These two outer connective tissue layers were first 
described by Ranvier in 1878 (Ranvier, 1878; Stolinski, 1995). Within the fascicles 
a delicate layer of connective tissue called the endoneurium surrounds each 
individual axon. The endoneurium contains endoneurial fluid, analogous to 
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cerebrospinal fluid in the CNS, and functions as the blood-nerve barrier (BNB), 
tightly regulating the endoneurial microenvironment (Weerasuriya and Mizisin, 
2011).  
 
Peripheral nerves also contain two types of Schwann cells: myelinating and non-
myelinating (ensheathing) Schwann cells. Myelinating Schwann cells form a 
layered myelin sheath around large calibre peripheral axons (Gaudet et al., 
2011). The sheath is interrupted by short lengths of exposed axonal membrane 
between Schwann cells, known as nodes of Ranvier.  These allow for fast 
saltatory conduction (from the Latin for ‘to leap’) of an action potential along a 
myelinated axon (Bear et al., 2001). Non-myelinating Schwann cells form a loose 
sheath around multiple small diameter axons, separating and surrounding 
them, and grouping them into what is known as a Remak bundle (Griffin and 
Thompson, 2008). 
 
1.2.1 Structure of the NMJ 
The NMJ was first described in 1862 by Wilhelm Friedrich Kühne. He described 
how nerve cells in a frog terminated on muscle, and coined the phrase 
‘neuromuscular junction’ (Kühne, 1862; Lopez-Munoz and Alamo, 2009). 
 
The NMJ is generally thought to be made up of three main cell types: the motor 
neuron, the skeletal muscle fibre and perisynaptic terminal Schwann cells. 
However, more recently a fourth cell type, termed a kranocyte, has also been 
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identified at the NMJ (Court et al, 2008). Each of these cell types is highly 
specialised according to the function that it has to perform.  
 
The nerve terminal of a motor neuron is specialised for neurotransmitter release. 
It contains large numbers of synaptic vesicles filled with the neurotransmitter 
acetylcholine, and mitochondria to provide the energy needed for 
neurotransmitter synthesis and release. Vesicles are found mainly in the part of 
the terminal nearest the muscle fibre, many are localized in active zones at the 
pre-synaptic membrane, ready to fuse and release acetylcholine into the 
synaptic cleft (Sanes and Lichtman, 1999).  
 
Directly opposite the nerve terminal lies the motor endplate of a skeletal muscle 
fibre. This is specialised to respond rapidly and efficiently to neurotransmitter 
released by the overlying nerve terminal, and has an extremely high 
concentration of acetylcholine receptors (Salpeter and Loring 1985). The 
postsynaptic membrane is folded into 1µm deep folds, known as junctional 
folds. These junctional folds are directly opposite the active zones in the pre-
synaptic terminal. Acetylcholine receptors are located at the top of the folds, and 
sodium channels are found at the bottom, an arrangement that leads to more 
efficient transmission (Wood and Slater 1997). 
 
Distinct from the Schwann cells of the axonal compartment of a motor neuron, 
perisynaptic terminal Schwann cells form a cap over the motor terminal 
branches and the nerve terminal. These Schwann cells are necessary for 
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maintaining the pre-synaptic structure and function of NMJs (Reddy et al, 2003), 
and aid path finding of neurons following injury. 
 
Kranocytes were first described in 2008 by Court and colleagues (Court et al, 
2008). These cells lie out with the synaptic basal lamina and form caps over the 
NMJ during postnatal development, for which the name ‘krano’, from the Greek 
word for helmet, is derived. Following denervation or paralysis they proliferate 
and spread throughout the perijunctional region before either Schwann cells or 
regenerating axons begin to sprout, thereby taking the lead in forming bridges 
between NMJs, suggesting that they may play a role in repairing neuromuscular 
connections in regeneration (Court et al, 2008).  
 
Finally, each muscle fibre is surrounded by a basal lamina, which also ensheaths 
the nerve terminal and terminal Schwann cells, although not kranocytes. The 
basal lamina passes between the pre-synaptic and post-synaptic membranes, 
through a gap known as the synaptic cleft (approximately 50nm wide) and 
extends down into the junctional folds of the post-synaptic membrane (Hughes 
et al., 2006). This synaptic portion of basal lamina is also specialised, containing 
a high concentration of acetylcholinesterase to break down acetylcholine 
released into the synaptic cleft but not activating a receptor (Krejci et al., 1997). It 
also contains the signalling molecules agrin and neuregulin (Sanes and 
Lichtman, 1999), necessary for the clustering of acetylcholine receptors at the 
motor endplate on the post-synaptic membrane (Reist et al., 1992; Sandrock et 
al., 1997). 
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1.3 Development of the PNS 
In its earliest stage (three weeks post gestation), an embryo is a flat disc of cells, 
three cell layers thick. These layers are termed the endoderm, mesoderm and 
ectoderm, and it is from the ectoderm that the entire nervous system, including 
the PNS, is formed. The part of the ectoderm that gives rise to the nervous 
system is the neural plate, and in a process known as neurulation the two edges 
of the neural plate move together and fuse to form the neural tube. The central 
nervous system is entirely formed from the walls of the neural tube. The tube 
itself eventually becomes the ventricular system (for review see Bear et al, 2002). 
 
As the two folds of the neural plate come together to from the neural tube some 
tissue is pinched off and ends up lying laterally to the tube. This is the neural 
crest, and is the source of all the cells of the PNS that have their cell bodies out 
with the CNS. At this stage of development the underlying mesoderm forms 
bulges on wither side of the neural tube, known as somites. These somites 
become the vertebrae of the spinal column and all related musculature, and it is 
from them that the term ‘somatic nervous system’ derives (for review see Bear et 
al, 2002). 
 
The rostral end of the neural tube differentiates to form the brain, while the 
caudal end becomes the spinal cord.  The neural tube narrows to become the 
spinal canal, and the tissue in the walls of the tube expands, eventually forming 
the dorsal horn and the ventral horn, where the cell bodies of lower motor 
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neurons are found after differentiation, projecting their axons out to the 
periphery (for review see Bear et al, 2002).  
 
In order to reach their intended target muscles lower motor neurons have to 
extend processes over large distances and form contacts with the correct muscle. 
In order to achieve this a neurite extends a growing tip called a growth cone (for 
review see Mueller, 1999). Growth cones are adapted to identify pathways for 
the neurite to grow down. Their leading edges are extremely motile, with a 
sheet called a lamellipodium from which filopodia rapidly form and then 
retract, probing the surrounding environment. If the extracellular matrix 
contains appropriate proteins, such as laminins, the filopodia attach to the 
substrate and pull the growth cone forward. In this way, axons are guided along 
the substrate by permissive cues, and prevented from moving in other 
directions by repellent ones (Mueller, 1999; Purves et al., 2004).  
 
1.3.1 Development of the NMJ 
When the growth cone of a growing lower motor neuron comes into contract 
with its target muscle fibre a NMJ is formed. Initially, the neuron secretes agrin 
into the basal lamina, where it interacts with muscle-specific kinase (MuSK) on 
the membrane of the muscle cell (Liyanage et al., 2002). MuSK interacts with 
rapsyn, which acts to pull acetylcholine receptors together to form a motor 
endplate on the post-synaptic membrane (for review see Sanes and Lichtman, 
1999).  
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Whilst the post-synaptic membrane is maturing the pre-synaptic nerve terminal 
also undergoes changes. Synaptic vesicles increase in number and become 
concentrated in newly formed active zones, and the synaptic area itself increases 
(Sanes and Lichtman, 1999; Takahashi et al., 1987). Specialisation of the motor 
nerve terminal only occurs when the nerve is in contact with a muscle fibre, 
leading to the theory that factors are secreted into the basal lamina by the 
muscle cell and act as retrograde signals causing the motor neuron to 
differentiate (Lupa et al., 1990). To date many factors have been identified and 
implicated in the formation of NMJs, but at present the precise mechanisms 
remain unknown. Factors implicated include fibroblast growth factors, laminin, 
collagen, glial cell line-derived neurotrophic factor (Gdnf). Proteins in the 
fibroblast growth factor family and collagen IV α2 are thought to be involved in 
the early stages of synaptic vesicle clustering, but are not necessary for the 
maturation of the nerve terminals. This instead depends on laminin β2 and 
other, synapse specific, isoforms of collagen IV (α3 and α6; Fox et al., 2007). 
Gdnf is expressed in muscle cells, but its receptors are expressed on motor 
neurons. It is critical for motor neuron survival, and activation of the receptors 
leads to maturation of the pre-synaptic terminal (Baudet et al., 2008), suggesting 
that Gdnf might be a muscle-derived factor regulating specialisation of the pre-
synaptic nerve terminal (for review see Wu et al., 2010). 
 
Initially each endplate is innervated by branches of several axons, and is said to 
be poly-innervated. During the first few weeks of post-natal development all 
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but one of these inputs withdraws and is lost in the process of synapse 
elimination, until all motor endplates are mono-innervated: one axon branch 
innervates one muscle fibre (Brown et al, 1976). Although branches of motor 
neurons are removed in synapse elimination, the number of motor axons 
innervating the muscle as a whole remains constant. Studies using XFP 
transgenic mice have shown that this process occurs asynchronously, and 
without any kind of spatial bias, suggesting that events occurring locally at each 
NMJ are responsible for the withdrawal of some inputs and the strengthening of 
others (Keller-Peck et al, 2001). However, the mechanisms regulating synapse 
elimination remain unclear, although activity appears to play a role, with active 
axons having a competitive advantage (Ribchester and Taxt, 1983; Balice-
Gordon and Lichtman, 1994). 
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1.4 Injury in the PNS 
 Under normal circumstances, peripheral nerves and their target muscles 
maintain stable connections throughout life. However, injury or disease can 
disrupt these connections with catastrophic consequences. 
 
Wallerian degeneration and dying-back neuropathy are distinct pathways 
known to be able to cause breakdown of axons and nerve terminals, and have 
distinct morphological characteristics (Murray et al., 2008b). Wallerian 
degeneration is associated with breakdown following traumatic nerve injury 
and with diseases such as Multiple Sclerosis, whereas motor neuron diseases 
such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) 
are associated with patterns of degeneration such as those seen in dying-back 
neuropathies (Murray et al., 2010). 
 
1.4.1 Wallerian Degeneration 
Wallerian degeneration was first described by the English physiologist 
Augustus Volney Waller in 1850 (Waller, 1850).  He sectioned the hypoglossal 
and glossopharyngeal nerves in the tongues of frogs, and recorded that distal to 
the injury (where the connection to the cell body is broken) the axon 
disintegrated and all debris was cleared away within a few days of injury, 
whilst the proximal section remained intact for a much longer period of time 
(Waller, 1850).  
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The first step in Wallerian degeneration is fragmentation of the nerve terminals 
and distal axons (Vial, 1958). This occurs within 24-48 hours in rodents 
(Beirowski et al., 2005), but in humans may take several days to initiate 
(Chaudhry and Cornblath, 1992). In the PNS myelinating Schwann cells respond 
to injury by altering gene expression (Guertin et al., 2005), no longer producing 
myelin proteins (Trapp et al., 1988) and degrading their own myelin (Gaudet et 
al., 2011). The myelin sheath around fragmenting axons is drawn back from the 
nodes of Ranvier to form distinct compartments called ‘ellipsoids’, in which the 
remaining axonal fragments are completely broken down (for review see 
Gillingwater and Ribchester, 2001). These ellipsoids are then removed by 
phagocytosing Schwann cells and invading macrophages, which are attracted to 
the site of injury by cytokines and chemokines secreted by Schwann cells and 
injured axons (Gaudet et al., 2011). 
 
At the same time, remaining Schwann cells proliferate and join together to form 
‘bands of Büngner’, which secrete many growth factors and aid in guiding 
regenerating proximal nerve stumps back to he denervated site (see section 1.4.3 
below; Gillingwater and Ribchester, 2001). 
 
At the NMJ, Wallerian degeneration is associated with mitochondrial damage, a 
reduction in the density of synaptic vesicles  (Winlow and Usherwood, 1975), 
and fragmentation of the nerve terminal, which becomes surrounded and 
eventually replaced by processes extended by terminal Schwann cells (Miledi 
and Slater, 1970).   
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1.4.2 Dying-back neuropathy 
In contrast to the rapid fragmentation along the length of the distal nerve seen 
in Wallerian degeneration, dying-back neuropathies are characterised by a wave 
of asynchronous withdrawal, starting at the NMJ. From the distal end of a nerve 
the degeneration then progresses retrogradely. There is no fragmentation of the 
nerve; instead the NMJs and distal axon appear to be reabsorbed into the axon, 
which ends in a retraction bulb (for review see Gillingwater and Ribchester, 
2003).  
 
A mouse model of dying-back neuropathy with a mutation known wasted has 
been used in this thesis (see chapter 3). Wasted is an autosomal recessive 
mutation in which the gene encoding translation elongation factor eEF1A2 is 
deleted (Chambers et al., 1998). eEF1A2 is one of two variant forms of eEF1A 
(the other being eEF1A1), which play a key role in protein synthesis (Condeelis, 
1995). At birth eEF1A1 is expressed ubiquitously, but its expression in nerve and 
muscle declines and is absent by P21 in mice (Pan et al., 2004). At this point 
eEF1A2 has normally replaced the role of eEF1A1, but is absent in wasted mice. 
Homozygous wasted mice therefore develop normally until P21, and then 
develop tremors, weight loss and an uncoordinated gait, which is followed by 
paralysis and death by P28 (Newbery et al., 2005). The pathology seen in these 
mice is due to dying-back neuropathy, leaving skeletal muscle denervated 
(Murray et al., 2008b).  
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1.4.3 Regeneration 
Unlike the CNS, the PNS has the ability to regenerate following degeneration. 
Following the clearance of debris distal to the injury the proximal stump of a 
peripheral nerve is able to sprout axons with growth cones. These axons are 
guided back to the remaining endoneurial tube from the degenerated portion of 
the nerve by chemotactic factors released by Schwann cells. These Schwann cells 
form bands of Büngner along which the regenerating axons can grow to reach 
their target muscle (Belkas et al., 2004). In humans large nerves can regrow up to 
5mm a day. 
 
At the cell body proteins associated with regeneration, such as actin, tubulin 
and growth associated proteins, are up-regulated (Fawcett and Keynes, 1990). 
The patterns of up-regulation recapitulate those seen in the development of the 
PNS (Miller et al 1989).  
 
Within a few hours of axotomy both myelinated and unmyelinated axons in the 
proximal stump begin to sprout. The mechanisms giving rise to regeneration at 
the axon tip are still unknown, but this rapid onset argues against control by the 
cell body, and rather for local control. Each axon can give rise to several new 
sprouts, which grow across the injury site until they make contact with the 
bands of Büngner, down which they can grow towards their target muscle. This 
process is considerably faster and more successful in crush injuries compared to 
transections, as the endoneurial tubes remain unbroken and there is no physical 
gap for the axons to cross (Fawcett and Keynes, 1990; Sunderland, 1978). Axons 
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therefore remain in their original ‘parent’ tubes and are guided back to their 
original target muscle fibre (Fawcett and Keynes, 1990).  
 
Interactions between axons and Schwann cells are essential for successful 
regeneration, as demonstrated by studies in which Schwann cells are killed, 
through freezing or by cytotoxic agents, and axons fail to regenerate (for review 
see Fawcett and Keynes, 1990; Hall, 1986). Whether an axon becomes 
myelinated or unmyelinated is dependent on the axon itself, rather than the 
previous role of the surrounding Schwann cells. Previously myelinated axons 
are remyelinated, and previously unmyelinated axons remain unmyelinated 
(Weinberg and Spencer, 1975).  
 
Once regenerating axons reach the NMJ the endplate is reinnervated by 
multiple inputs in way that replicates neonatal development. As in development 
excess inputs are pruned back until all motor endplates are mono-innervated 
(Barry and Ribchester, 1995).  
 
1.5 Diseases of the PNS 
 Diseases affecting the motor neurons are broadly termed motor neuron disease 
(MND), although this term covers a number of different diseases. All are 
characterised by degeneration of motor neurons, atrophy of skeletal muscle and 
associated loss of movement. ALS and SMA are two of the most common forms 
of MND. In both these diseases NMJs appear to be an early pathological target 
(Murray et al., 2010)  
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1.5.1 ALS 
The French neurologist Jean-Martin Charcot first described ALS in 1869 
(Charcot and Joffroy, 1869). It is a late onset and progressive neurodegenerative 
disease, and the most common form of adult motor neuron disease with a 
prevalence of 1 in 50,000. It is characterised by loss of both upper and lower 
motor neurons resulting in muscle atrophy, weakness and spasticity. ALS is 
fatal, usually due to denervation of respiratory muscles and the diaphragm, 
which occurs within 5 years of disease onset in most cases (for review see Boillée 
et al, 2006; Rothstein, 2009).  
 
Although 90-95% of cases of ALS are sporadic, the remaining 5-10% of cases are 
inherited (Cleveland and Rothstein, 2001). Through identification of genes 
involved in these familial cases, and the development of transgenic animal 
models, some light has been shed on the potential mechanisms underlying ALS. 
Approximately 20% of cases of familial ALS are caused by mutations in the 
Cu/Zn superoxide dismutase (SOD1) gene (Rosen et al, 1993).  
 
1.5.2 SMA 
SMA is a childhood form of motor neuron disease. SMA is the leading genetic 
cause of infant mortality and, after cystic fibrosis, the most common autosomal 
recessive illness in humans. It has an incidence of 1 in 6000 and a carrier 
frequency of 1 in 35 (Monani, 2005).  
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SMA is also a progressive neurodegenerative disease, but unlike ALS is 
characterised by lower motor neuron death with no upper motor neuron 
involvement. Symptoms include weakness and atrophy of voluntary muscles, 
which is often more severe in the legs than the arms (Wirth, 2000). Those 
affected may have difficulty feeding and have increased susceptibility to 
respiratory tract infections. Pneumonia is a common cause of death in SMA 
patients (Hardart et al. 2002).  
 
95% of SMA patients have a deletion of the survival motor neuron 1 gene 
(SMN1), leading to a loss of function of SMN protein (Cifuentes-Diaz et al, 2001; 
Le et al. 2005; Monani, 2005). The remaining 5% have mutations within the same 
gene. In humans and higher primates a highly homologous gene termed 
centromeric SMN (SMN2) also produces SMN protein, but chiefly produces a 
transcript missing exon 7 (SMN Δ7) and only low levels of full length SMN.  
Therefore a greater copy number of SMN2 gives rise to a milder phenotype of 
the disease by producing higher levels of full length SMN protein (Monani, 
2005).  
 
1.5.3 NMJs as early pathological targets 
NMJs and distal axonal compartments have been shown to be early pathological 
targets and to play a critical role in neuronal loss in many neurodegenerative 
diseases in both the PNS and CNS, including ALS and SMA (Wishart et al., 
2006). Studies of NMJs from both ALS patients and animal models demonstrate 
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degeneration of NMJs before any changes are seen in the proximal axon or soma 
(Fischer et al., 2004).   
 
It is not yet clear why NMJs are particularly vulnerable, but the theory of 
compartmentalised neurodegeneration proposes that synapses, axons and 
neuronal soma have distinct responses to degenerative stimuli (Gillingwater 
and Ribchester 2001). The molecular mechanisms behind NMJ breakdown 
remain unclear, however, a number of potential cellular pathways that could 
contribute to NMJ dysfunction have been identified (Murray et al., 2010). These 
include disruption of axonal transport and cytoskeletal architecture, oxidative 
stress and mitochondrial disruption, endoplasmic reticulum stress, RNA 
processing and growth factor signalling (for review see Murray et al., 2010). 
 
Previous therapeutic strategies against neurodegenerative disease have targeted 
the neuronal cell body, but have failed to prevent degeneration of axons and 
synapses (Chiesa et al., 2005; Sagot et al., 1995). The body of evidence 
highlighting synapses as early pathological targets in a range of 
neurodegenerative conditions, along with increasing understanding of cellular 
pathways underlying synaptic loss, offers the potential to target therapeutic 
strategies to this particularly vulnerable region of the neuromuscular system, 
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1.6 Factors influencing the PNS 
Identification of genetic factors that influence the form and function of the PNS 
in vivo is important in aiding our understanding of the neuromuscular system in 
health and disease. For this reason I have studied the effect of three different 
genes on the PNS: yellow fluorescent protein (YFP), apolipoprotein E (APOE) 
and ERCC1 (excision repair cross-complementing group 1).  
 
1.6.1 YFP 
YFP is a widely used tool in many different biological systems. Its use as a 
reporter gene since its discovery in the 1960s by Shimomura and colleagues 
(Shimomura et al, 1962) has been instrumental in many breakthroughs. It is 
commonly used under the control of a thy-1 promoter to visualise the nervous 
system, under the assumption that it is biologically inert (Feng et al., 2000). 
However, cells expressing XFPs contain large amounts of a foreign protein, 
which has previously been shown to induce a cell stress response (Detrait et al., 
2002; Liu et al., 1999). My first hypothesis, therefore, is that YFP is not an inert 
reporter protein, but has effects throughout the PNS.  
 
1.6.2 ApoE 
ApoE is a lipid transport protein with three naturally occurring isoforms in the 
human population, termed apoE2, apoE3 and apoE4 (Utermann et al, 1977). 
Previous work has shown that these isoforms differentially affect outcome in the 
CNS following traumatic brain injury, and the age of onset and progression in a 
number of CNS diseases, including Alzheimer’s disease and Parkinson’s disease 
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(Millar et al., 2003; Strittmatter et al., 1993; Zareparsi et al., 1997). Despite a 
number of studies on the effect of the isoforms on diseases of the PNS, results 
remain inconclusive (Geranmayeh et al., 2005). My second aim is therefore to 
determine whether or not the different isoforms of apoE differentially affect 
rates of degeneration and regeneration in the PNS.  
 
1.6.3 ERCC1 
Ercc1 is a DNA repair protein. It functions as part of a heterodimer with 
xeroderma pigmentosum group F (XPF), playing a role in the nucleotide 
excision repair pathway (NER), and in repairing some double strand breaks and 
interstrand crosslinks (Ahmad et al., 2008; Bergstralh and Sekelsky, 2008; Gregg 
et al., 2011). Deficient DNA repair mechanisms are linked to cancer and 
accelerated aging (de Boer and Hoeijmakers, 2000; Schumacher et al., 2008), and 
have also been implicated in neurodegeneration (Kraemer et al., 2007; Rass et 
al., 2007). As NMJs are primary pathological targets in many neurodegenerative 
diseases (Wishart et al., 2006) I have used mice deficient in Ercc1 in order to 
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1.7 Aims 
 
Hypothesis I: YFP is not an inert reporter protein, but has effects throughout the PNS. 
Aim I: Investigate the effect of YFP on the PNS. 
i. Examine the levels of cell stress proteins in YFP spinal cord. 
ii. Examine the effect of expression of YFP on the morphology of NMJs in 
healthy adult mice. 
iii. Investigate the effect of YFP on the time course of Wallerian degeneration 
following nerve injury and in pathological dying-back neuropathy. 
 
Hypothesis II: ApoE isoforms differentially affect degenerative and regenerative events 
in the PNS. 
Aim II: Investigate the effect of the apoE3 and apoE4 transgenes on the PNS. 
i. Examine the effect of expression of the apoE transgenes on the 
morphology of NMJs and peripheral nerve in healthy adult mice. 
ii. Compare the rate of Wallerian degeneration in mice expressing apoE3 or 
apoE4 after a nerve crush injury. 
iii. Compare the rate of subsequent regeneration and neuromuscular 
reinnervation in mice expressing apoE3 or apoE4. 
 
Hypothesis III: Loss of Ercc1 leads to pathological changes at the NMJ. 
Aim III: Investigate the effect of the loss of Ercc1 at the NMJ. 
i. Examine the effect of loss of Ercc1 on the morphology of the NMJ. 
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ii. Quantify levels of neuromuscular innervation in Ercc1∆/- mice at different 
ages. 
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Chapter 2 - General Materials and Methods  
 
All materials and methods presented in this chapter are general, and have been 
used for experiments throughout this thesis. For detailed materials and methods 




Mice were anaesthetised by inhalation of halothane (2% in 1:1 N2O/O2) before 
exposing the sciatic nerve in the thigh, the tibial nerve above the heel or the 
intercostal nerves following the line of the ribs. For nerve crush surgeries 
pressure was applied between a pair of fine-point forceps for 30 seconds. Nerves 
were checked to ensure a complete crush had been performed before suturing 
the skin and allowing the mouse to recover. For nerve cut experiments, a ~1mm 
section of nerve was removed to ensure complete transection. Post-operative 
mice were kept in standard animal house conditions.  
 
2.2 Quantitative fluorescent (Li-COR) western blots  
Total protein was isolated from distal nerve stumps, entire dissected sciatic 
nerves or spinal cords. Protein was separated by SDS/Polyacrylamide gel 
electrophoresis on 4-20% pre-cast NuPage 4-12% Bis Tris gradient gels 
(Invitrogen) and then transferred to PVDF membrane overnight. The 
membranes were blocked for 30 minutes using 5ml Odyssey blocking buffer (Li-
	   26	  
COR) and incubated overnight with 3µl primary antibody (Actin – Abcam; apoE 
- Millipore; Caspase 1 and CCL3 – Abcam; GFP – Millipore; STI1 – BD 
Biosciences). Secondary antibodies were added at a concentration of 1µl/ml in 
PBS and membranes were incubated for two hours (Donkey anti goat IRDye 
680, goat anti mouse IRDye 800, goat anti mouse IRDye 680 and goat anti rabbit 
IRDye 680 - Odyssey). Blots were imaged using an Odyssey Infrared Imaging 
System (Li-COR Biosciences). Quantification was performed on single channels 
with the analysis software provided. Bands were identified by their molecular 
weight and normalised to controls. The arbitrary fluorescence intensity was 
calculated using Odyssey software.  
 
2.3 Immunohistochemistry 
Mice were sacrificed by inhalation of isofluorane (2% in 1:1 N2O/O2) or 
perfusion fixation with 0.1M PBS containing 4% paraformaldehyde. The levator 
auris longus (LAL; from the dorsal/ posterior surface of the neck; Murray et al., 
2008a), transversus abdominis (TA; from the anterolateral abdominal wall; 
Murray et al., 2008b), first to third deep lumbricals (from the plantar surface of 
the hind-paw; Murray et al., 2010) and/or flexor digitorum brevis muscles (FDB; 
from the plantar surface of the hind-paw; Murray et al., 2010) were dissected in 
oxygenated mammalian physiological saline (mM: NaCl 120, Kcl 5, CaCl2 2, 
MgCl2 1, NaH2PO4 0.4, NaHCO3 23.8, D-glucose 5.6). Muscles were then fixed 
for 30 minutes in 0.1M PBS containing 4% paraformaldehyde (Electron 
Microscopy Science).  
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All non-FP muscles were exposed to α-bungarotoxin (BTX) conjugated to the 
fluorescent label tetramethyl-rhodamine isothiocyanate (TRITC-α-bungarotoxin; 
5mg/ml, Molecular Probes) for 30 minutes to label post-synaptic acetylcholine 
receptors. Acetylcholine receptors in YFP muscles were labelled with α-
bungarotoxin conjugated to Alexa Fluor® 647 (Alexa 647-α-BTX; 5mg/ml, 
Invitrogen). 
 
Muscles were then immunohistochemically processed to allow visualisation of 
pre-synaptic nerve terminals. Muscles were blocked in 4% bovine serum 
albumin (BSA) and 1.5% TritonX in 0.1M PBS for 30 minutes before incubation 
in primary antibodies directed against 145kDa neurofilament proteins (1:300 
dilution; Millipore) overnight. After washing for 2 hours in 0.1M PBS, non-FP 
muscles were incubated for 4 hours in a 1:30 dilution of swine anti-rabbit 
secondary antibody conjugated to the fluorescent label fluorescein 
isothiocyanate (FITC; Dako). YFP muscles were incubated for 4 hours in a 1:30 
dilution of swine anti-rabbit secondary antibody conjugated to TRITC (Dako). 
Muscles were then whole-mounted in Mowoil® (Calbiochem) on glass slides 
and cover-slipped for subsequent imaging. 
 
2.4 Microscopy 
Fluorescently labelled muscle preparations were viewed using either a standard 
epi-fluorescence microscope equipped with a chilled CCD camera (40x 
objective; 0.8NA; Nikon IX71 microscope; Hammamatsu C4742-95), or a laser 
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scanning confocal microscope (63x objective; 1.4NA; Zeiss Axioskop). For 
confocal microscopy, the 488nm, 543nm and 647nm laser lines were used for 
excitation and confocal Z-series were merged using Zeiss software. All images 
were taken using sequential laser capture and with the excitation/emission 
spectra set to ensure no bleed-through between channels. Images were 
assembled for analysis using Adobe Photoshop.  
 
2.5 Quantification of NMJs 
A minimum of 50 NMJs, selected at random but spread across the entire muscle, 
were assessed in each muscle preparation. Muscles where antibody staining was 
too faint to quantify due to poor antibody penetration and muscles with damage 
to either the muscle fibres or nerves from dissection were excluded from further 
analysis. All analysis was performed blind to the genetic status of the material.  
 
For occupancy counts endplates were categorised as vacant (no neurofilament 
overlying the endplate), partially occupied (neurofilament partially overlying 
the endplate) or fully occupied (neurofilament entirely overlying the endplate). 
For quantification of developmental synapse elimination or pathological levels 
of poly-innervation, fully occupied endplates were further subdivided based on 
the number of axonal inputs contacting the endplate. For neuromuscular 
reinnervation experiments, an individual endplate had to be fully occupied by 
an incoming single axon profile to be considered reinnervated.  
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2.6 Statistical analysis 
All data were collected into Microsoft Excel spreadsheets and analysed using 
GraphPad Prism software. All bar charts shown are mean ± SEM. Statistical 
significance was considered to be p<0.05 for all analyses. Individual statistical 
tests used are detailed in figure legends. 
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Chapter 3 - YFP 
 
3.1 Introduction 
Green fluorescent protein (GFP) was first discovered, almost accidently, in 1961. 
Osamu Shimomura and colleagues were trying to purify aequorin, a protein 
from the jellyfish Aequorea Victoria that fluoresces blue in the presence of Ca2+ 
(Shimomura et al., 1962). During the purification of aequorin they noted a 
second protein in the jellyfish extract, which appeared “slightly greenish in 
sunlight”.  This protein was named GFP, and was hardly used again until 
Martin Chalfie realised that it might be useful as a fluorescent marker to study 
gene expression and protein localisation in Caenorhabditis elegans over thirty 
years later (Chalfie et al., 1994). 
 
Work carried out in the Chalfie lab in the early 1990s showed that the formation 
of the GFP chromophore did not need any other substrates or enzymes from the 
jellyfish, and that it could be expressed in other species (Chalfie et al., 1994).  
Variants of GFP were then engineered by Roger Tsein to improve on the original 
wt-GFP, so that the fluorescent proteins used in research today have improved 
biophysical properties, such as more efficient protein folding, as well as a 
number of spectrally distinct colour variants (reviewed by Cubitt et al., 1995; 
Heim et al., 1994; Heim and Tsien 1996). These colour variants include yellow, 
cyan, red and blue, as well as the original green. Collectively the fluorescent 
proteins are termed XFPs. 
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From that time onwards GFP and its variants have been a hugely important 
biological marker/molecular imaging tool, and its discovery and refinement 
lead to Shimomura, Chalfie and Tsien receiving the Nobel Prize for Chemistry 
in 2008. 
 
GFP has several advantages making it an excellent biological marker. First it is 
small – the peptide consists of only 298 amino acids (Prasher et al., 1992) and 
exists as a monomer, which allows it to diffuse through cells more easily than 
other, larger markers such as β-galactosidase. Second, GFP is heritable, meaning 
that GFP expressing strains could be established. Third, the chromophore (the 
part of the molecule responsible for giving GFP its colour) is encoded entirely by 
the polypeptide chain. This means that no other exogenous substrates or co-
factors are needed to cause fluorescence and that living cells can be viewed non-
invasively, simply by viewing them under blue light (Chalfie et al., 1994).  
Fourth, GFP can be fused to other proteins without loss of fluorescence, making 
it very valuable as a biological marker. Finally, different spectral variants of GFP 
have been developed (Cubitt et al., 1995; Heim and Tsein, 1996; Heim et al., 
1994). These different fluorophores can be used in conjunction with each other, 
allowing for studies examining the co-expression of different genes. 
 
In 1995 Ikawa et al produced the first lines of GFP transgenic mice. In trialling 
different promoters and different variants of GFP they produced mice that 
expressed GFP ubiquitously (Ikawa et al., 1995). The lines of mice used in the 
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current study express YFP selectively in neurons, and were generated in 2000 by 
Feng et al. (Feng et al., 2000). This group produced 25 lines of transgenic mice 
expressing each of the four spectral variants (GFP, YFP, CYP, RFP) under the 
control of the thy1 promoter. Thy1 is a cell surface glycoprotein which is part of 
the immunoglobulin superfamily (Gordon et al., 1987). Its name is derived from 
its expression in thymocytes, but it is also expressed on the surface of neurons 
throughout the nervous system (Morris, 1985) making it ideal for use as a 
neuronal-specific promoter. Although all of the founder thy1-YFP mice were 
generated using the same construct, each of the lines produced had a unique 
pattern of expression within the neurons that proved to be hereditable. This 
observation indicated that insertion site and / or copy number could play a role 
in XFP expression.  
 
The variations in expression patterns in the thy1-XFP mice included differences 
in the intensity of the XFP labelling, different cell types expressing fluorescent 
protein, and variable proportions of neurons being labelled (Feng et al., 2000). In 
this study, two lines of the thy-1 mice have been used: YFP-16, which express 
YFP in all motor neurons, and YFP-H, in which only a minority of the motor 
neurons fluoresce. The YFP-H mice have the particular advantage of allowing 
the comparison of neurons expressing YFP and non-fluorescent neurons within 
the same muscles from individual mice, thereby eliminating any complications 
caused by background strain differences that may arise from using non-YFP 
mice for controls.  
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Feng et al (2000) assessed the toxicity and phototoxicity of YFP using in vivo 
imaging of YFP labelled NMJs. Identified NMJs were imaged over a time course 
of 8 weeks to 9 months. The only changes identified were those typically 
associated with aging, i.e. a change in the staining pattern with the staining of 
both the motor nerve terminal and endplate becoming ‘spotty’ (Balice-Gordon 
and Lichtman, 1990). Additional NMJs were imaged for longer sustained time 
periods and every 2 minutes during the process of reinnervation, but no 
changes were detected and the process of reinnervation continued as normal. 
Feng et al therefore concluded that expression of fluorescent proteins in neurons 
had no discernable effect on neuronal morphology or any detectable level of 
toxicity (Feng et al., 2000). This conclusion was in agreement with other reports 
that suggested that XFPs are biologically inert (Ikawa et al., 1998; Lichtman and 
Sanes, 2003; Okabe et al., 1997). Thus, the underlying assumption is that the 
presence of fluorescent protein has no effect on the cellular or molecular 
composition of the neuron. 
 
Neurons in the thy1-XFP mice contain large amounts of a foreign protein, the 
presence of which has been shown to alter cellular and molecular characteristics 
of living cells in other experimental model systems in vivo and in vitro, 
triggering stress responses and pathological changes. In 1999 Liu et al noted a 
link between expression of GFP and induction of apoptosis in three cell lines, 
and noted that this finding “should promote studies of GFP cytotoxicity and 
attempt to isolate new non-toxic mutants of GFP” (Liu et al., 1999). When 
Huang et al introduced mice over-expressing GFP in the heart as an extra, 
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transgenic, control group for a study of cardiac hypertrophy they noticed that 
the ‘control’ GFP group developed dilated cardiomyopathy, and that the 
severity was dose-dependent (Huang et al., 2000).  The effect of reporter genes 
on primary cortical neurons was directly investigated in 2002 by Detrait and 
colleagues (Detrait et al., 2002). They reported that GFP expression induced 
apoptotic cell death in the neurons more rapidly than other reporter genes 
(Detrait et al., 2002). Taken together, these studies potentially contradict the 
findings of Feng et al. (2000), indicating that XFPs are not inert, particularly 
when highly expressed. My hypothesis is therefore that YFP is not an inert 
reporter protein, but that its expression can influence the form and function of 
the PNS. 
 
In order to test this hypothesis I have investigated whether expression of yellow 
fluorescent protein modifies the form and function of the healthy and 
pathological PNS in vivo. I have used RT-PCR, western blotting and 
immunohistochemistry to examine the levels of cell stress proteins in the spinal 
cord of YFP mice. I have also used immunohistochemistry and confocal 
microscopy to study the effect of expression of YFP on morphology of NMJs in 
healthy adult mice, and investigate the effect of YFP on the time course of 
Wallerian degeneration following nerve injury and in pathological dying-back 
neuropathy.
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3.2 Materials and methods 
 
3.2.1 Mice 
Breeding colonies of thy1-YFP-H mice (Feng et al., 2000) and thy1-YFP-16 mice 
(hereafter referred to as YFP-H and YFP-16, respectively), both on a C57BL/6J 
background, were initially purchased as breeding pairs from Jackson 
Laboratories and established and maintained in animal care facilities at the 
University of Edinburgh. Young adult YHP-16 mice were compared with non-
FP C57BL/6J mice from the same breeding colony. In experiments using YFP-H 
mice non-FP motor units within the same mice were used as internal controls. 
The YFP status of mice was ascertained by examining ear punches for evidence 
of YFP-labelled neurons innervating the skin. To determine the effects of YFP on 
dying-back pathology, YFP-H mice were crossed with wasted mice, a model of 
dying-back pathology (Murray et al., 2008b; Newbury et al., 2005). YFP-H mice 
were crossed with wasted mice for two generations in order to obtain 
homozygous wasted mice expressing YFP in a subset of neurons. Wasted/YFP-H 
mice were genotyped using standard PCR techniques. Primers used were: 
Wasted wild-type  Forward:  TAGTGGCTCCTTGGAACAG 
   Reverse:  CTACTCTCCCTGAATGCCTT 
Wasted knockout Forward: ATAAGCTCCCCAATGGTAGAGAA 
Reverse: CGCGCCATTCTTGTATTGTT 
Wasted genotype was determined by presence or absence of a band of the 
appropriate size following separation by gel electrophoresis. Wasted/YFP-H 
mice were taken for analysis at post-natal day 24 (late-symptomatic). The 
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banked tissue from a previous, now defunct, colony of strongly expressing thy1-
YFP-16 mice was obtained from mice originally supplied to Dr Simon Parson at 
the University of Leeds by Jackson Laboratories. Animals were housed in 
standard SPF conditions and all procedures were carried out under licensed 
authority from the UK Home Office. 
 
3.2.2 Cell stress array 
Mouse cell stress focused pathway arrays in a 96-well plate format (PAM-003A), 
compatible with an ABI 7000 real-time PCR machine, were used to assay 
changes in cell stress gene expression (three comparisons for YFP-16 and three 
for wild-type controls, each comparison composed of pooled tissue from three 
individual mice). Samples were added to the reaction plate and signal 
amplification by PCR was carried out using Sybr-Green ‘1 step qRT-PCR kit’ 
(Invitrogen). Analysis was carried out using the Analysis Suite spreadsheet 
provided by Tebubio SuperArrays. Gene functions listed in table 3.1 were 
obtained from the SuperArray product specification sheets.  
 
3.2.3 Quantitative fluorescent (Li-COR) western blots  
See general materials and methods, section 2.2. 
 
3.2.4 Spinal cord immunohistochemistry 
Entire vertebral columns were removed and collected into 4% 
paraformaldehyde solution for 1 hour. The spinal cord was removed from the 
vertebral column and further fixed for 30mins before being washed in 1xPBS 
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and embedded in 2% low-melting point agarose. The embedded spinal cords 
were mounted on a vibratome and cut coronally at a thickness of ~200µm for 
immunohistochemical staining. Sections were blocked in 4% bovine serum 
albumin (BSA) and 1.5% TritonX in 0.1M PBS for 30 minutes before incubation 
in primary antibodies directed against caspase 1 (1:500 dilution; Abcam) 
overnight. Sections were washed for 2 hours in 0.1M PBS, and then incubated 
for 2 hours in a 1:30 dilution of swine anti-rabbit secondary antibody conjugated 
to the fluorescent label tetramethyl-rhodamine isothiocyanate (TRITC, Dako). 
Sections were co-stained with fluorescent nuclear dye (TO-PRO 3, Molecular 
Probes). Sections were then whole-mounted in Mowoil® (Calbiochem) on glass 
slides and cover-slipped for imaging. 
 
3.2.5 NMJ Immunohistochemistry  
See general materials and methods, section 2.3. 
 
3.2.6 Surgery 
See general materials and methods, section 2.1, for surgery overview. Intercostal 
nerve cuts have been used to obtain results presented in this chapter. Initially I 
attempted to study the effects of YFP expression on Wallerian degeneration 
using our standard nerve axotomy protocol – cutting the tibial nerve leading to 
denervation of the deep lumbrical muscles of the hind paw. Whilst 
immunohistochemistry confirmed that the nerve cut itself was successful very 
little YFP was expressed in the lumbrical muscles, both in terms of the number 
of motor units fluorescing and the levels of fluorescence seen. Despite a number 
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of attempts I was unable to use the lumbrical muscles to view Wallerian 
degeneration in the presence of YFP.  
 
A different muscle preparation commonly used in the lab is the LAL muscle, 
which is innervated by the facial nerve. I next attempted to denervate this 
muscle, as previous work on YFP mice has shown that it often has a number of 
YFP expressing motor units in YFP-H mice (see Fig. 3.7 and 3.11 for confocal 
micrographs of YFP expression in the LAL). However, the nerve innervating it 
is relatively short and could only be accessed behind the ear of the mouse, 
making it very difficult to visualise and meaning that the muscle was often 
damaged in the surgery.  
 
I then attempted to denervate the transversus abdominis muscle. Fewer motor 
units express YFP in this muscle compared to the LAL, but it has the advantage 
of being innervated by the intercostal nerves, which can be axotomised far 
enough from the TA to avoid damaging the muscle in the surgery.  Once the 
intercostal nerves innervating the area of the TA that I was able to dissect out for 
immunohistochemistry were identified this preparation proved to be the most 
successful, and was the protocol I used to obtain nerve cut data comparing YFP 
and non-FP nerves in the same muscle (Fig. 3.1).  
 
The high frequency of YFP-positive motor units and the high levels of 
fluorescence seen in the LAL muscle, in comparison to the infrequent, low 
intensity labelling in the lumbricals indicates a possible proximal to distal 
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gradient of YFP expression in these YFP-H mice. This is supported by the 
intermediate numbers of YFP-positive motor units observed in the TA, a muscle 


















Figure 3.1 – Adaptation of surgical protocol in YFP-H mice (over page). Flow 
chart showing the changes in method for nerve cut surgery to allow for both an 
accessible nerve and good YFP expression.  
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3.2.7 Microscopy 
See general materials and methods, section 2.4.  
 
3.2.8 Quantification of NMJs 
Quantitative analysis was performed on images obtained from the confocal 
microscope with the YFP channel initially excluded, so that the operator did not 
know the YFP status of the tissue being analysed. For analysis of neurofilament 
accumulation in normal tissue endplates were assigned a score between 0 and 5, 
with 0 being healthy NMJs with no evidence of neurofilament accumulation and 
5 being nerve terminals with large aberrant accumulations of neurofilament. 
The YFP channel was revealed subsequent to quantification to determine the 
YFP status of each nerve terminal. For occupancy counts in Wasted/ YFP-H mice 
undergoing dying-back pathology, endplates were categorised as either 
partially occupied (neurofilament partially overlying the endplate) or fully 
occupied (neurofilament entirely overlying the endplate). Vacant endplates 
were excluded from analysis since there was no way to tell their YFP status. 
 
3.2.9 Statistical analysis 
See general materials and methods, section 2.6. 
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3.3 Results 
 
3.3.1 YFP expression activates cell stress responses in neurons in vivo.  
To begin with I investigated whether expression of yellow fluorescent protein 
modifies neuronal cell stress pathways in vivo, using cell stress pathway-specific 
RT2 profiler PCR arrays. This allowed me to quantify and compare expression of 
known cell stress-related genes in the spinal cord of YFP-16 mice compared to 
C57-Bl6 wild-type controls. YFP-16 mice from our breeding colony appeared 
grossly identical to those previously reported in the literature, expressing YFP in 
the vast majority of neurons in the PNS (Feng et al., 2000). However, nearly half 
of all the cell stress genes (41 out of 84) examined on the PCR array were up-
regulated more than 1.5-fold in spinal cord from YFP-16 mice compared to 
controls (table 3.1 and Fig. 3.2). Of these, 10 genes (24%) had expression levels 
increased greater than 2-fold, including genes involved in cell stress activation, 
inflammation, DNA damage and repair and apoptosis (table 3.1).  
 
To confirm that the RNA changes observed in YFP-16 mouse spinal cord 
resulted in corresponding changes at the protein level, I selected two proteins 
which had greater than 2-fold up-regulation in YFP-16 mice, caspase 1 and 
CCL3, for validation using quantitative fluorescent western blot. Caspase 1 has a 
role in apoptosis signaling, and CCL3 in inflammation. A further stress 
inducible protein, STI1, which was not included on the PCR array, was also 
selected for western blot. Expression levels of both caspase 1 and CCL3 were 
dramatically increased in the YFP-16 spinal cord (1000 fold and 100 fold 
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respectively, when normalised to wild-type, Fig. 3.3), in agreement with the 
mRNA data. STI1 was expressed at an equivalent level in wild-type and YFP-16 
tissue, showing that there was not a universal up-regulation of stress-related 
proteins in the YFP-16 spinal cord. YFP protein was found only in samples from 
YFP-16 mice, and not seen in the controls, confirming genotyping (Fig. 3.3A).  
 
I verified that levels of YFP were directly responsible for the cell stress response 
by comparing the levels of caspase 1 in YFP-16 mouse spinal cord with levels in 
YFP-H mouse spinal cord. YFP-H mice only express YFP in a small subset of 
neurons, compared to the majority of neurons in the YFP-16 line. Increased 
expression of caspase 1 correlated directly with the amount of YFP present, as 
levels in YFP-16 mouse spinal cord were 70-fold higher than levels in YFP-H 
mice (Fig. 3.4). 
 
I further confirmed the YFP expression in neurons was directly triggering cell 
stress responses by using immunohistochemistry for caspase 1 expression in 
YFP-H mouse spinal cord. Increased caspase 1 levels were restricted to cells 
expressing YFP (Fig. 3.5). It was important to ensure that there was no bleed-
through between the channels imaging YFP and caspase 1, as this could lead to 
a signal being picked up in the TRITC channel that was actually due to the YFP 
rather than immunohistochemistry against caspase 1. To avoid this all images 
were taken using sequential laser capture and with the excitation/emission 
spectra set as narrowly as possible to avoid overlap between the channels. Lack 
of bleed-through was confirmed by the presence of information in the YFP 
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channel that was not seen in the TRITC channel. Similarly structures marked by 
the caspase immunohistochemistry have not all shown in the YFP channel (Fig. 
3.6). 
 
Taken together, these data demonstrate that expression of YFP in mouse 
neurons in vivo activates a robust cell stress response at both the RNA and 
protein level.  
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Table 3.1 - Mouse SuperArray data showing greater than 1.5 fold cell stress 
RNA expression changes in the spinal cord of YFP-16 mice compared with wild-
type controls. Note that none of the genes on the array were found to be 
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significantly down-regulated 1.5 fold in YFP-16 mouse spinal cord. (Array cell 
refers to the location on the 3D bar chart in Fig. 3.2). 




Figure 3.2 - YFP expression in neurons activates cell stress responses at the 
RNA level in vivo. 3D bar chart showing fold-differences in mRNA expression 
levels for 84 cell stress related genes comparing spinal cord from YFP-16 mice 
with wild-type (C57-Bl6) mice (N=3 samples, each consisting of pooled tissue 
from 3 mice. Each bar on the graph represents the mean of the 3 samples. The 
colours of the bars do not represent anything specific, but are intended to make 
viewing the graph clearer).  






Figure 3.3 - YFP expression in neurons leads to corresponding up regulation 
of cell stress proteins. A: Representative fluorescent western blots for cell stress 
proteins in the spinal cord of wild-type and YFP-16 mice. Both caspase 1 and 
CCL3 had increased expression in YFP-expressing tissue, in agreement with 
RNA data (Fig. 3.2). A control cell stress protein, STI1, which did not appear in 
the SuperArray, remained at the same level as seen in wild-type mice. Western 
blots for GFP confirmed genotype. B: Bar chart (mean±SEM) showing 
quantification of protein expression levels in YFP-16 spinal cord (normalised to 
wild-type: fluorescence intensity ratio of 1 = same as wild-type), confirming a 
~50-fold increase in levels of CCL3 and ~1000-fold increase in levels of caspase 1 
(N=3 samples, each consisting of pooled tissue from 3 mice). 








Figure 3.4 – Increased caspase 1 levels correlate with levels of YFP. A: 
Representative fluorescent western blots for caspase 1 and GFP in the spinal 
cord of wild-type, YFP-H and YFP-16 mice. Increased caspase 1 expression 
correlated directly with the amount of YFP present. B: Bar chart (mean±SEM) 
showing quantification of protein expression levels in wild-type, YFP-H and 
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Figure 3.5 – Increased expression of caspase 1 is restricted to YFP expressing 
cells. Representative confocal micrograph showing caspase 1 
immunohistochemistry in the spinal cord of a YFP-H mouse. A: Confocal 
micrograph showing endogenous YFP labelling of two cells in the spinal cord of 
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a YFP-H mouse. B: Caspase immunohistochemistry showing strong caspase 
labelling of the same two cells, indicating an up-regulation of caspase (a cell 
stress marker), which is restricted to YFP-positive neurons. C: TO-PRO staining 
for nuclear DNA, showing the nuclei of both the two YFP neurons and all other, 
negatively labelled, cells (three examples of which are marked with asterisks). 
D: Confocal micrograph showing panels A-C merged. Increased expression of 
caspase 1 was seen in YFP-positive neurons in all of the sections imaged (N=5 
sections). Scale bar = 20µm. 
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Figure 3.6 – Increased levels of caspase seen in YFP positive cells are not due 
to bleed-though. Representative confocal micrographs showing caspase 1 
immunohistochemistry in the spinal cord of a YFP-H mouse. A/B: Lack of bleed-
through between the yellow (YFP) and red (caspase 1/TRITC) channels is 
confirmed by the presence of information in the YFP channel which is not seen 
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in the TRITC channel (marked by arrows in panel A) and caspase staining in the 
TRITC channel which is not seen in the YFP channel (marked by asterisks in 
panel B). C: TO-PRO staining for nuclear DNA. D: Confocal micrograph 
showing panels A-C merged. Scale bar = 20µm. 
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3.3.2 YFP expression in motor neurons subtly disrupts neuronal morphology. 
I next sought to establish whether activation of cell stress pathways in YFP-
expressing neurons had any adverse effects on neuronal morphology. I first 
examined the morphology of lower motor neurons innervating the LAL muscle 
in YFP-H mice. The advantage of this strain of YFP mice is that they only 
express YFP in a fraction of motor neurons. This allowed me to compare YFP-
expressing neurons with non-FP neurons side-by-side in the same muscle, 
eliminating any potential for background strain differences (Fig. 3.7A). Care was 
taken to ensure that all quantification was performed blind by first quantifying 
with the YFP channel removed from all confocal micrographs, thus basing 
analysis on the neurofilament staining alone for all NMJs. The YFP channel was 
then replaced in order to gain the YFP status of each NMJ.  
 
As previously reported, all NMJs in 2-4 month old YFP-H mice were fully 
innervated by a single motor axon (Fig. 3.7A; Feng et al 2000). However, higher-
resolution analysis showed a significant increase in abnormal accumulations of 
neurofilaments in distal axons and motor nerve terminals when YFP was 
present. NMJs were assigned a score between 0 (no neurofilament 
accumulation) and 5 (large accumulations of neurofilament). Non-FP NMJs only 
rarely had a score greater than 1, whereas YFP containing terminals frequently 
showed neurofilament accumulation that scored 3 or higher. This morphology is 
similar to cytoskeletal changes considered to represent early pathological 
changes in neurons (Fig. 3.7B-E; Mi et al., 2005; Murray et al., 2008a).  
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Retrospective examination of banked tissue from a now defunct YFP-16 mouse 
colony from the University of Leeds with very high YFP expression levels (~7 
times greater than those found in our standard YFP-16 colony) revealed more 
severe morphological abnormalities. Motor neurons in these mice had both 
large swellings and vacuoles in pre-terminal axons and very high levels of 
neurofilament accumulation. This again suggests a dose-dependent effect of 
YFP (Fig. 3.8).  
	   56	  
 
 
Figure 3.7 - YFP expression in motor neurons subtly disrupts neuronal 
morphology. A-D: Representative confocal micrographs of NMJs in the LAL 
muscle from a YFP-H mouse labelled to reveal neurofilaments (NF: red) and 
postsynaptic motor endplates (BTX: blue). Note how only a small proportion of 
motor axons were YFP-positive in these mice, but that all motor endplates were 
innervated (A). Panels B-D show high power micrographs of NMJs identified in 
panel A. The main panels show the respective NMJs with the YFP channel 
removed, as they were viewed for quantification. The insets show the same 
NMJs with the YFP channel replaced in order to ascertain the YFP status of the 
terminal. Note how YFP-positive NMJs had abnormal accumulations of NF in 
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the motor nerve terminal (compare C&D with B). E: Bar chart (mean±SEM) 
showing quantification of NF accumulation in motor nerve terminals from YFP-
H mice (0=no accumulation; 5=large abnormal accumulation), revealing 
significant increases in NF accumulation in YFP-positive terminals (P<0.001; 
Mann-Whitney test, two-tailed; N=5 mice, n=9 muscles;). Scale bars = 80µm (A), 
40µm (B-D).  Ailish Nimmo assisted with obtaining some data, during a summer 
project supervised by L.Comley. 

















Figure 3.8 – Increased incidence of morphological abnormalities at the NMJ in 
tissue with increased expression of YFP. A: Bar chart (mean±SEM) showing 
fluorescent western blot quantification of YFP protein expression levels in the 
sciatic nerve of YFP-16 mice from the current Edinburgh colony (low 
expression) compared to levels in tissue banked from a high-expressing colony 
from the University of Leeds (P<0.01; unpaired two-tailed t-test; N=3 mice).  B-
C: Representative micrographs showing NMJ morphology in low-expressing 
YFP-16 mice (B) compared to high-expressing YFP mice (C). Note the presence 
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of both neurofilament accumulations (white arrow) and vacuoles (blue arrow) in 
the axons of the high-expressing mouse. Tissue from the colony of high-expressing 
YFP-16 mice was obtained by Dr Simon Parson. 
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3.3.3 YFP expression in neurons alters response to dying-back neuropathy but not 
Wallerian degeneration. 
It has previously been suggested that modulation of cell stress pathways can 
alter the response of neurons to neurodegenerative stimuli (Wishart et al., 2008; 
Xu et al., 2005), therefore I next addressed whether YFP also affected 
neurodegeneration pathways in vivo. This was done using two 
neurodegenerative pathways with distinct molecular mechanisms: Wallerian 
degeneration and dying-back pathology (see general introduction, section 1.4).  
 
In order to investigate the effect of YFP expression on Wallerian degeneration 
intercostal nerves were crushed in YFP-H mice (see materials and methods, 
section 3.2.6). The TA muscles, which these nerves innervate, were dissected 
and fixed 20 hours later. This allowed me to analyse nerve bundles containing 
both FP-positive and –negative axons at an intermediate state of degeneration. 
Fragmentation was occurring in both FP-positive and –negative axons at this 
time point, indicating that the time-course and morphological correlates of 
Wallerian degeneration following nerve lesion were not altered in YFP-
expressing motor neurons (Fig. 3.9). However, in a number of cases the YFP 
protein itself appeared to be preserved, whereas viewing the muscle with only 
neurofilament staining and the YFP channel removed showed the same axons in 
a fragmented state (Fig. 3.10).  This suggests that although YFP does not affect 
the time course of the degeneration process itself, it may be slower to be cleared 
away during debris clearance following breakdown than other cytoskeletal 
proteins such as neurofilaments. 
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In contrast, in wasted mice, where loss of translation elongation factor eEF1A2 is 
known to cause dying-back pathology (see general introduction, section 1.4.2; 
Murray et al., 2008b), the majority of YFP-expressing neurons remained intact 
whilst neighbouring non YFP-expressing neurons were in the final stages of 
degeneration, even at late-symptomatic ages (P24, Fig. 3.11). Therefore, dying-
back pathology was significantly attenuated in YFP-expressing motor neurons. 
Quantification was performed with the YFP channel removed so occupancy was 
based solely on the amount of neurofilament overlying the endplate. This both 
minimized the potential for operator bias and removed the possibility that any 
retention of YFP as seen in the Wallerian degeneration study could lead to an 
over-estimation of occupancy in the YFP expressing terminals.  
 
Taken together, these data show that YFP has differing effects on different 
neurodegenerative pathways, with unpredictable consequences.  




Figure 3.9 - YFP expression does not alter responses to Wallerian degeneration 
in vivo. A-B: Representative confocal micrographs of intramuscular axons 
supplying the transversus abdominis muscle from YFP-H mice (also labeled to 
reveal NFs; red), before (A) and 20 hours after (B) intercostal nerve lesion. The 
presence of YFP did not alter the time-course or morphological appearance of 
Wallerian degeneration after nerve injury, with NF fragmentation occurring in 
YFP-positive and –negative axons at the same rate in all nerves examined (N=6 
mice, n=6 nerves). Scale bar = 30µm. 





Figure 3.10 - YFP expression persists in axons undergoing Wallerian 
degeneration. A-C: Representative confocal micrograph of  intramuscular axons 
supplying the transversus abdominis muscle from YFP-H mice 20 hours after 
intercostal nerve lesion. When viewed on just the YFP channel the axons 
expressing YFP appear to be preserved (A), but NF labeling reveals that the 
axons are already fragmented at this time point, and are indistinguishable from 
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YFP-negative axons (B). C: Merged image showing both YFP and NF channels. 
Scale bar = 30µm. 
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Figure 3.11 - YFP expression alters responses to dying-back pathology in 
wasted mice. A-D: Representative confocal micrographs of two NMJs in the 
LAL muscle from a late-symptomatic (P24) wasted/YFP-H mouse labeled to 
reveal NFs (red) and postsynaptic motor endplates (BTX: blue). Note how the 
motor axon with YFP (bottom NMJ) remained intact whereas the motor axon 
without YFP (top) was undergoing retraction, characteristic of a dying-back 
pathology. All quantification was performed with the YFP channel removed.  E: 
Bar chart showing quantification of dying-back pathology at the NMJ in late-
symptomatic (P24) wasted/YFP-H mice, revealing a significant attenuation of 
dying-back pathology in YFP expressing motor nerve terminals (i.e. a retention 
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of endplates fully occupied by overlying NFs and a reduction in the numbers of 
partially occupied endplates; P<0.001; Mann-Whitney test, two-tailed; N=4 
mice, n=7 muscles). Scale bar = 50µm. 
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3.4 Discussion 
In this chapter I have shown that expression of YFP in neurons in vivo activates a 
cell stress response, in contradiction with previous studies that have reported it 
to be biologically inert (Feng et al., 2000; Ikawa et al., 1998; Lichtman and Sanes, 
2003; Okabe et al., 1997). I have used cell stress arrays, western blotting and 
immunohistochemistry to show that an up-regulation of cell stress responses in 
YFP mice is present at both the RNA and protein level, and that it is the 
presence of YFP itself which is causing this response. I have also shown that 
expression of YFP alters neuronal morphology in otherwise healthy nerves, and 
alters the time course of dying-back pathology in wasted-YFP-H mice, but does 
not delay the onset of Wallerian degeneration after nerve injury.  
 
The finding that YFP induces a cell stress response is perhaps unsurprising, 
considering that neurons expressing YFP contain large amounts of a foreign 
fluorescent protein. Such fluorescent proteins are known to be capable of 
altering the cellular and molecular characteristics of living cells in other 
experimental model systems in vivo and in vitro, e.g. the cardiovascular system, 
triggering pathological changes (Huang et al., 2000; Liu et al., 1999). Huang and 
colleagues have previously reported a dose-dependent effect of GFP expression 
in the hearts of mice expressing GFP.  In these mouse lines higher GFP levels 
gave rise to dilated cardiomyopathy (Huang et al., 2000). The force generating 
ability of isolated ventricular cardiomyocytes is also thought to be impaired by 
GFP expression (Nishimura et al., 2006). These muscle specific effects of XFP 
expression could be linked to impaired myosin-actin interactions in GFP 
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expressing myocytes – GFP binds preferentially to myosin heads disrupting the 
binding of actin (Agbulut et al., 2006; Agbulut et al., 2007). 
 
My cell stress array picked up a greater than 1.5 fold increase in expression 
levels in 41 different cell stress genes in the YFP-16 spinal cord compared to 
wild-type. These genes are known to be involved in a number of different cell 
stress responses, including apoptosis.  An early study on XFPs focused on the 
potential apoptotic effect of GFP (Liu et al., 1999). In setting out to look at how 
the brightness of fluorescence affected the rate of photo bleaching this group 
noticed that a high percentage of their cells “contracted, rounded up and 
disappeared”. They went on to show that the presence of GFP in the cells was 
activating cell death through apoptosis (Liu et al., 1999). Detrait and colleagues 
also reported an apoptotic effect of GFP when comparing the effects of three 
different reporter genes on primary cortical neurons (Detrait et al., 2002). They 
also showed that the rate of cell death correlated with the level of expression of 
GFP. This is consistent with my finding that increased levels of YFP expression 
in the mouse spinal cord correlate with increased levels of caspase 1 
(interleukin-1b converting enzyme), a protein known to be involved in the 
induction of cell death (Miura et al., 1993).  
 
The increased levels of caspase and other genes relating to apoptosis in the YFP 
mice have implications for previous studies. Mahajan and colleagues used XFPs 
as biological markers to study the activation of specific caspases at the onset of 
apoptosis (Mahajan et al., 1999). Another group developed GFP expressing cells 
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lines as a tool for analysing apoptosis and necrosis in vitro (Strebel et al., 2001). 
In both cases, the up-regulation of apoptosis related genes in the YFP mice could 
impact on the results reported.  
 
Over a third of up-regulated genes in the cell stress array had known roles in 
oxidative and metabolic stress pathways (15 out of 41). As long ago as 1996 it 
was reported that exciting GFP for extended periods of time could generate free 
radicals that are toxic to the cell and contribute to oxidative stress (Clontech user 
manual, 1996). Greenbaum and colleagues showed that photoactivation of GFP 
generated endogenous singlet oxygen, which damaged the chromophore and 
lead to photobleaching (Greenbaum et al., 2000). GFP has also been shown to 
increase the sensitivity of cell lines to cytotoxic drugs in assays of antineoplastic 
drugs by increasing oxidative stress (Goto et al., 2003). RNA for the heat shock 
70-related protein APG-2 (hspa4) was up-regulated in the cell stress array. 
Elevating concentrations of GFP in the cytoplasm of endothelial cells causes a 
dose-dependent up-regulation of heat shock protein 70 (HSP70) mRNA and 
protein (Zhang et al., 2003). Synthesis of HSP70 is also specifically increased 
during cell stress conditions (Kiang and Tsokos, 1998). 
 
Interestingly, Caine et al use GFP in a study of the Alzheimer’s Aβ peptide, 
fusing Aβ to the fluorescent protein in order to monitor its expression in yeast 
(Caine et al., 2007). They showed a lower growth yield and increased heat shock 
response in their Aβ-GFP and GFP-Aβ cells compared to controls, and 
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concluded that this was due to the presence of Aβ. However, in studies such as 
this it would be preferable to use a different reporter molecule or 
immunocytochemistry when appropriate antibodies are available, in order to 
rule out any confounding effects of GFP on the results. YFP and GFP are also 
commonly used to tag mutant and wild-type SOD1 in order to visualise its 
intracellular localisation in ALS studies (Corti et al., 2004; Matsumoto et al., 
2005; Zhang and Zhu, 2006). However, when Stevens and colleagues compared 
GFP-tagged wild-type and mutant SOD1 protein they found that the presence of 
GFP was altering some of the physiochemical properties of the SOD1 (Stevens et 
al., 2010). They highlight the need for other studies using GFP tagged proteins to 
interpret results carefully, and not to assume that untagged proteins will always 
behave in the same way. 
 
My results show that at the molecular level, expression of YFP in neurons 
instigates cell stress pathways and is not biologically inert. This finding 
provides evidence, supported by a number of other studies, that expression of 
fluorescent proteins in cells and tissues can alter molecular composition. The 
precise molecular mechanisms by which this occurs are not yet known, but 
warrants further investigation. 
 
The second part of this chapter looked at the effects of YFP expression on the 
form of the healthy and pathological PNS in vivo. YFP mice have been a valuable 
tool for morphological studies of the nervous system in vivo for over ten years. 
In particular, the YFP-H strain, in which approximately 3% of axons are labelled 
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(Beirowski et al., 2004; Feng et al 2000), has allowed visualisation of entire 
individual motor axons. The potential to reconstruct entire neurons in these 
mice has lead to breakthroughs such as a greater understanding of the 
asynchronous nature of synapse elimination (Keller-Peck et al., 2001).  
 
Morphological abnormalities have previously been reported in YFP-H mice; 
Bridge and colleagues have shown that there is a dose-dependant increase in 
axonal swellings in the gracile system of these mice with age (Bridge et al., 
2009). Accumulations of other proteins have also been shown to cause axonal 
swellings and neurodegeneration in several disease models including 
Parkinson’s disease (Martin et al., 2006) and giant axonal neuropathy (Allen et 
al., 2005). Despite this YFP has been used as a tool for studying the mechanisms 
of neurodegeneration in vivo (Beirowski et al., 2004). Here I have shown that 
YFP causes morphological abnormalities at the NMJ, with accumulations of 
neurofilament, which increase in a dose dependant manner.  
 
Expression of YFP also has unpredictable effects on degenerative pathways. YFP 
expressing axons in wasted/YFP-H mice had significantly attenuated dying-back 
pathology, and whilst the rate of Wallerian degeneration wasn’t affected per se 
several axons retained YFP expression after neurofilament proteins had begun 
to fragment. It is not clear if the retained NMJs in the YFP-positive neurons in 
the wasted/YFP-H mice were still functional, or if the presence of YFP in these 
neurons was merely preventing retraction of the nerve terminal without 
preserving function. It is possible that the increased expression of cell stress 
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proteins, instead of being detrimental, actually leads to a priming response in 
the YFP-positive neurons, making them more able to cope when external 
stressors are applied to them. If this is the case then a pathological insult such as 
the loss of eEF1A2 in the wasted mice could have less of an effect on the YFP-
positive neurons than on the non-FP controls. Further work is needed to confirm 
or deny this hypothesis, and to elucidate the mechanisms by which YFP is 
attenuating dying-back pathology in the wasted/YFP-H mice. 
 
A limitation of this study is the lack of quantitative data for the rate of Wallerian 
degeneration in YFP-positive neurons compared to non-FP neurons. The 
difficulties in finding a nerve cut protocol to allow visualisation of this process 
restricted the time available for this, but ideally degeneration at the NMJ could 
be quantified to give further insights into what may be happening in YFP-
positive neurons.  
 
The morphological findings reported in this chapter highlight the need to use 
adequate controls to ensure that any findings are occurring as a result of 
experimental intervention and not due to the expression of YFP. Where possible 
immunohistochemical labelling of cytoskeletal proteins can be used to ensure 
that situations where YFP persists after other proteins have degenerated, as seen 
here during Wallerian degeneration, are recognised.  
 
YFP is one of the most powerful tools in modern neuroscience, with advantages 
over other methods of visualising the nervous system. However, the findings 
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reported here support the hypothesis that XFPs are not innocuous, inert reporter 
proteins, and indicate that care should be taken when using them, particularly 
when studying molecular mechanisms or neurodegeneration in mice expressing 
fluorescent proteins in neurons. Further work is now needed in order to 
determine the mechanisms by which fluorescent proteins induce the cell stress 
response seen in neurons, and to discover if this is due to the presence of the 
protein itself, or due to its fluorescent properties.  
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Chapter 4 - ApoE  
 
4.1 Introduction 
Apolipoprotein E (apoE) is a 34kDa plasma protein that facilitates the transport 
of cholesterol and other lipids via its interactions with low-density lipoprotein 
receptors (Mahley, 1988). Initially called arginine-rich apoprotein, apoE was 
discovered in 1973 by Shore and Shore, as a protein component of lipoproteins 
(Shore and Shore, 1973). Early studies in a number of species highlighted the 
importance of apoE in cholesterol metabolism (Mahley, 1988). Throughout the 
last 40 years apoE has been the focus of intensive research which has 
highlighted roles for it in atherosclerosis and heart disease, as well as several 
biological processes which are potentially unrelated to its lipid transport role, 
including neurological disease, immunoregulation and susceptibility to 
infectious disease (for review see Mahley et al., 2009). 
 
ApoE is polymorphic in humans (Utermann et al., 1977; Utermann et al., 1980; 
Zannis et al., 1981), although other non-human primates show no 
polymorphism, and express only one form of apoE (Zannis et al., 1985). The 
polymorphism in humans occurs as a result of three alleles, termed ε2, ε3 and 
ε4, that occur at a single locus. These three alleles give rise to one of three 
isoforms, apoE2, apoE3 or apoE4, which give six phenotypes - three 
homozygous phenotypes (E4/4, E3/3, and E2/2) and three heterozygous 
phenotypes (E4/3, E3/2, and E4/2, Zannis et al, 1982). The most common 
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phenotype is apoE3/3 and the distribution of alleles in the human population is 
thought to be approximately 8% for ε2, 75% for ε3 and 15% for ε4 (Utermann et 
al., 1982). 
 
Analysis of the amino acid sequence of the three apoE isoforms identified the 
molecular basis of the polymorphism. The three isoforms differ from each other 
by two amino acid substitutions, at residues 112 and 158. ApoE3 has cysteine at 
residue 112 and arginine at residue 158, while apoE4 has arginine and apoE2 
cysteine at both sites (Rall et al., 1982; Weisgraber et al., 1981). The entire apoE 
protein has two structural domains: an N-terminal domain consisting of four-
helix bundle, which contains the receptor binding site of the protein, and a C-
terminal domain containing the major lipid binding region. The two domains 
are linked by a flexible hinge region (Wetterau et al., 1988). Substitution of 
cysteine for arginine at residue 112 in apoE4 leads to a change in orientation of 
arginine-61, which then interacts with the C-terminal domain causing a change 
in conformation of the protein (Dong et al., 1994). This altered conformation 
distinguishes apoE4 from both the apoE2 and apoE3 isoforms, and is thought to 
be the cause of the isoform specific effects of apoE (Fig. 4.1). 
 
ApoE is primarily synthesised in the liver, by hepatic parenchymal cells, but 
unlike other apolipoproteins apoE is also produced by many other tissues 
throughout the body (Elshourbagy et al., 1985). It is abundant in the brain, 
where expression levels reach approximately a third of those seen in the liver 
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(Elshourbagy et al., 1985). Within the CNS apoE is synthesised primarily by 
astrocytes and macrophages (Basu et al., 1981; Boyles et al., 1985; Pitas et al., 
1987). However, neurons in certain regions of the brain have also been shown to 
be capable of synthesising apoE (Aoki et al., 2003; Xu et al., 1999). ApoE has also 
been shown to be the major apolipoprotein in CSF (Roheim et al., 1979). In the 
PNS apoE is known to be synthesised by non-myelinating Schwann cells and 
macrophages, though whether or not it can also be produced intraneuronally is 
yet to be established (Boyles et al., 1985; Stoll and Müller, 1986). 
 
In 1993 Strittmatter and colleagues reported an association between APOE 
genotype and incidence of familial late-onset Alzheimer’s disease (Strittmatter et 
al., 1993). In this study they showed that the frequency of the apoE ε4 allele was 
significantly higher in patients suffering from Alzheimer’s than in age-matched 
controls. Since that time numerous studies have confirmed that APOE4 
genotype is a major risk factor in Alzheimer’s disease (Corder et al., 1993: 
Saunders et al., 1993a: Saunders et al., 1993b), as well as in several other CNS 
neurodegenerative conditions, including Parkinson’s disease (Li et al., 2004a; 
Zareparsi et al., 1997). The APOE4 genotype is also associated with poor 
outcome after head injury, stroke, intracerebral haemorrhage and traumatic 
spinal cord injury (Alberts et al., 1995; Horsburgh et al., 2000; Jha et al., 2008; 
McColl et al., 2007; Millar et al., 2003; Teasdale et al., 1997). Conversely, APOE3 
has been shown to provide a neuroprotective effect on CNS degeneration in 
conditions such as Wilson’s disease (Schiefermeier et al., 2000a) and on 
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neurological outcome following cardiopulmonary resuscitation (Schiefermeier 
et al., 2000b). 
 
In 1994 Nathan and colleagues reported that apoE affected neuronal growth in 
vitro in an isoform specific manner (Nathan et al., 1994). Cultured dorsal root 
ganglion neurons incubated with lipids had enhanced neurite outgrowth in the 
presence of apoE3, and inhibited neurite outgrowth in the presence of apoE4 
(Nathan et al., 1994; Nathan et al., 1995). In order to produce these isoform 
specific effects apoE binds to and internalises lipoproteins, itself becoming 
intracellular in the process, where the different isoforms accumulate at different 
concentrations within the cells and have differing effects on the neuronal 
cytoskeleton (Ji et al., 1998; Nathan et al., 1995). ApoE3 is retained in both the 
cell bodies and neurites of neural cells in vitro at much higher concentrations 
than apoE4, and supports microtubular structure, whereas apoE4 is associated 
with microtubule depolymerisation within neurons (Nathan et al., 1995). These 
findings provided evidence that apoE had a role in neurobiology, and isoform 
specific effects on the nervous system.   
 
Although the influence of apoE genotype on CNS injury and disease is well 
established, there is only a partial understanding of any potential influence of 
apoE genotype on the PNS in vivo (Bedlack et al., 2000; Geranmayeh et al., 2005). 
ApoE is expressed throughout the PNS, including at the NMJ (Akaabourne et 
al., 1994). Increased levels of apoE production have been noted during 
maturation of peripheral nerves in newborn rats (Müller et al., 1985) and a 
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several hundred-fold increase in synthesis and secretion has been reported in 
the distal segments of peripheral nerves following nerve injury and exposure to 
harmful environmental stimuli (Gelman et al., 1987; Ignatius et al., 1986; Skene 
and Shooter, 1983; Snipes et al., 1986). Up-regulation of apoE is also seen in the 
injured optic nerve and spinal cord; however, unlike in the PNS it fails to 
accumulate in the injured CNS (Skene and Shooter, 1983).  The accumulation of 
apoE in the PNS following nerve injury occurs over the same time period as 
regeneration of the sciatic nerve (Skene and Shooter, 1983), and remains 
elevated if the nerve is prevented from regenerating by axotomy (Müller et al., 
1985). These observations indicate a role for apoE in nerves undergoing growth 
or regeneration, potentially in the clearance of lipids from the site of injury 
during Wallerian degeneration, and in transferring them among macrophages, 
Schwann cells and axons during subsequent regeneration of peripheral nerves 
(Boyles et al., 1985; Boyles et al., 1989; Ignatius et al., 1986; Skene and Shooter, 
1983). 
 
An association between APOE genotype and disease outcome in the PNS has 
been demonstrated for diabetic neuropathies (Bedlack et al., 2003; Tsuzuki et al., 
1998) and HIV-associated peripheral neuropathy (Corder et al., 1998). As within 
the CNS the ε4 allele is commonly associated with increased risk and faster 
progression of disease.  
 
A number of studies have investigated the effect of APOE genotype on 
progression and outcome in motor neuron disease but the results have been 
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inconclusive. Some studies have reported an association between apoE 
genotype and MND or ALS: both Al-Chalabi et al and Drory et al found that the 
frequency of the ε4 allele was increased in the patient group compared to the ε3 
or ε2 forms, and Drory and colleagues found that patients with an ε4 allele had a 
shorter survival time than those without (Al-Chalabi et al., 1996; Drory et al., 
2001). Moulard and colleagues found no difference in the frequency of the 
genotypes between ALS patients and controls, but reported that apoE4 patients 
had an earlier age of onset, and that patients with an ε2 allele had a longer 
duration of disease (Moulard et al., 1996). A more recent study by Li and 
colleagues has also reported an association between apoE genotype and ALS, 
but this time found an effect only of the ε2 allele, which they showed was 
protective against an earlier age of onset (Li et al., 2004b). These studies support 
the protective role of apoE2 and deleterious role of apoE4 seen in studies of the 
CNS and the role of apoE in Alzheimer’s disease. However, other studies have 
reported a lack of association between apoE genotype and either age of onset, 
frequency of each of the apoE alleles or duration of disease in ALS (Bachus et al., 
1997; Mui et al., 1995; Siddique et al., 1998; Smith et al., 1996). One possible 
reason for the discrepancies between studies is that they are patient cohort 
studies, which often have small sample sizes, which can confound results. At 
present the influence of APOE genotype on events in the PNS remains 
controversial. 
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Previous studies using genetically-modified animals have investigated the 
effects of complete loss of apoE on regenerative events in the PNS, and have 
reported that regeneration occurs normally in the absence of apoE (Genden et 
al., 2002; Popko et al., 1993). However, these studies have not looked at the 
influence of loss of apoE on degeneration, nor have they looked at the effects of 
different APOE genotypes, as is seen in the human population, on degenerative 
or regenerative events. I have therefore examined the influence of apoE 
genotype on the PNS using a transgenic mouse model expressing human apoE3 
or apoE4 isoforms, established by Xu and colleagues in 1996 (Xu et al., 1996). 
This group used a background strain of mice that lacked a functional mouse 
APOE gene (Piedrahita et al., 1992) to allow the study of the different human 
apoE isoforms without interference from endogenous mouse apoE. Founder 
mice for the human apoE isoforms were generated by micro-injection of human 
APOE genomic DNA fragments. These founder mice were then back-crossed 
with apoE knockout mice to produce mice that had a homozygous deletion of 
mouse apoE and were hemizygous for a human apoE transgene (either E2, E3 or 
E4). These mice express human apoE at physiological levels, and have 
expression patterns of apoE found in humans and other non-human primates 
(Xu et al., 1996). They also have the advantage of allowing us to study the 
influence of APOE genotype on the PNS with control over other confounding 
factors (such as genetic background) that can make human studies less reliable 
(Gerenmayeh et al., 2005).  
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Here, I have used apoE3 and apoE4 mice to investigate isoform-specific effects 
of human apoE on the form, function and molecular composition of the healthy 
and degenerating mouse PNS. ApoE2 mice were not used as they express apoE 
at levels much higher than the apoE3 or apoE4 mice (Xu et al., 1996); this would 
have made it impossible to determine whether any effects observed were due to 
the genotype or were simply occurring due to differences in expression levels of 
apoE. I have used immunocytochemistry, electrophysiology, confocal 
microscopy and electron microscopy to compare the processes of development, 
degeneration and regeneration of lower motor neurons in mice expressing 
apoE3 and apoE4, and iTRAQ proteomics to investigate potential molecular 
mechanisms regulating apoE-specific responses in the PNS in vivo.  
 
Figure 4.1 – Model of the domain structure of apoE3 and apoE4 (over page). 
ApoE has two structural domains: an N-terminal domain consisting of four-
helix bundle (red - helix 1; blue - helix 2; green - helix 3; yellow - helix 4), and a 
C-terminal domain modelled as a series of α-helices. The two domains are 
linked by a flexible hinge region. Helix 4 of the N-terminal domain contains the 
receptor binding site of the protein, and the C terminal domain contains the 
major lipid-binding region. The cysteine at residue 112 in apoE2 (not shown) 
and apoE3 (A) is replaced by arginine in apoE4 (B). This causes a reorientation 
of arg-61 to a position where it interacts with glu-255 in the C-terminal domain, 
giving apoE4 (B) a more compact structure, and distinguishing it from the more 
extended structure of both apoE2 and apoE3 (A). (Adapted from Zhong and 
Weisgraber, 2009). 
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4.2 Materials and methods 
 
4.2.1 Mice 
Young adult mice expressing human apoE4 were compared with non-apoE 
littermates (apoE-/-) or apoE3 mice. These mice lack endogenous mouse apoE 
to allow the study of the effects of the human isoforms without interference 
from mouse apoE. Mice were supplied via a collaboration with Dr. Allen Roses 
(Duke University) and breeding colonies established at the University of 
Edinburgh. Despite both apoE3 and apoE4 strains of mice being kept in 
identical conditions, the apoE3 colony produced litters much more infrequently 
than the apoE4 colony (unexplained observation). This has lead to the omission 
of apoE3 data from some experiments (detailed in results section for each 
specific experiment). 
 
APOE knockout mice were generated on a C57Bl/6J background by disrupting 
the endogenous mouse APOE gene with the neomycin-resistance gene 
(Piedrahita et al., 1992). Human apoE4 and apoE3 transgenic mice have been 
generated on this apoE-deficient background by microinjection of human APOE 
genomic DNA fragments (Xu et al., 1996). As the precise regulatory elements 
necessary for the expression of APOE were unknown large upstream and 
downstream regions were included in the genomic DNA fragments in order to 
ensure the inclusion of the regulatory regions (Xu et al., 1996).  
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ApoE4 and apoE3 founder mice were backcrossed with apoE-knockout mice for 
more than 10 generations resulting in mice hemizygous for the human apoE 
transgenes E4 or E3 on a homozygous mouse apoE-knockout background. The 
apoE3 and apoE4 mouse lines used throughout this chapter have been shown to 
express apoE at physiological levels, similar to those found in humans 
(Horsburgh et al., 2000; Xu et al., 1996). ApoE was shown to be expressed in the 
brain, liver, kidney spleen, heart, skeletal muscle, intestine, serum and neurons 
in the transgenic mice (Xu et al., 1996). 
 
The presence of human apoE transgenes on an established knockout 
background was determined by western blot analysis (See general materials and 
methods, section 2.2). All animals were housed in standard SPF conditions and 
all procedures were carried out under licensed authority from the UK Home 
Office. 
 
For initial experiments apoE-/- mice were compared with age-matched 
C57Bl/6J (wild-type) mice in order to examine the influence of loss of apoE, and 
confirm that apoE-/- mice were functioning as expected prior to the addition of 
human apoE3 or apoE4. C57Bl/6J mice were used as non-littermate wild-type 
controls, as this is the background strain that the apoE-/- mice were produced 
from.  
 
4.2.2 Quantitative fluorescent (Li-COR) western blots  
See general materials and methods, section 2.2. 
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4.2.3 Electron microscopy 
5mm sections of peripheral nerves (distal to the injury site if following surgery, 
see general materials and methods, section 2.1) were dissected out in 0.1M PBS 
and fixed in ice-cold 0.1M phosphate buffer containing 4% 
paraformaldehyde/2.5% glutaraldehyde. Nerves were post-fixed in 1% osmium 
tetroxide overnight. Following dehydration through an ascending series of 
ethanol solutions and propylene oxide, nerves were embedded in Durcupan 
resin. Ultrathin sections (~60 nm) were cut and collected on formvar-coated 
grids (Agar Scientific, UK), stained with uranyl acetate and lead citrate and then 
quantitatively assessed in a Philips CM12 transmission electron microscope 
(TEM) equipped with a Gatan camera (Comley et al., 2011; Gillingwater et al., 
2002). Images were imported into ImageJ software for quantitative analysis. 
Individual high power micrographs were reconstructed to form entire nerve 
cross sections in Adobe Photoshop. Higher power images were taken to allow 
assessment of small myelinated and unmyelinated axon profiles (see section 
4.2.4). All analysis was performed blind to the genetic status of the material to 
avoid bias. 
 
4.2.4 Regenerating peripheral nerve quantification 
Initially attempts to quantify regenerating axons were based solely on the 
number of myelinated profiles present in an entire nerve bundle (Fig. 4.2B). The 
disadvantage of this method was that it did not take into account the number of 
small unmyelinated profiles or any axons still in the early stages of myelination. 
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Thus, it was possible that the number of myelinated axons could remain 
relatively unchanged in apoE3 and apoE4 regenerating nerves, whilst the axon 
density or total axon number was altered.  
 
To overcome this I next quantified individual high-resolution images from 
selected regions of a nerve in order to be able to count unmyelinated axons as 
well as the more obvious myelinated profiles. This produced a density 
measurement of axons in the sciatic nerve of each genotype, but did not take 
into consideration the fact that the total axon number could be altered by 
genotype due to a change in the overall size of the regenerating nerve (Fig. 
4.2C).  
 
As it was not possible to count the total number of axons in an entire nerve I 
then took measurements of the total cross sectional area of reconstructed sciatic 
nerves from apoE3 and apoE4 mice using image J software. This allowed me to 
scale up axon density counts from individual images to estimated total axon 
counts from entire nerves of different genotypes (Fig. 4.2D). This approach 
avoided the pitfalls of sampling only a subset of axons and so missing a change 
in total axon number, and overcame the possibility that packing density itself 
had not changed between the genotypes, but that overall number was changed 
due to smaller overall size of regenerating nerves. Ideally the total number of 
axons in a few nerves of each genotype could be counted in order to check for 
the accuracy of this approach, but time limitations prevented this.  
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Figure 4.2 – Adaptation of quantifying method of regenerating apoE3 and 
apoE4 peripheral nerves (over page). A: Flow chart showing progression of 
changes in method of quantifying regenerating peripheral nerves from apoE3 
and apoE4 mice 3 weeks after sciatic nerve crush. B: Bar chart (mean±SEM) 
showing total number of myelinated axons in sciatic nerve of apoE3 and apoE4 
mice 3 weeks after sciatic nerve crush (P>0.05; t-test, two-tailed; apoE3 N=3, 
apoE4 N=3; ns = not significant). C: Bar chart (mean±SEM) showing number of 
axons (myelinated and unmyelinated) per 2500µm2 in sciatic nerve of apoE3 and 
apoE4 mice 3 weeks after sciatic nerve crush (P>0.05; t-test, two-tailed; apoE3 
N=9, apoE4 N=7; ns = not significant). D: Bar chart (mean±SEM) showing a 
significant difference in estimated total axon number (myelinated and 
unmyelinated) in sciatic nerve of apoE3 and apoE4 mice 3 weeks after sciatic 
nerve crush 3 weeks (P<0.05; t-test, two-tailed; apoE3 N=11, apoE4 N=11). 
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4.2.5 Surgery 
See general materials and methods, section 2.1. Tibial and sciatic nerve crushes 
and cuts have been used to obtain results presented in this chapter.  
 
4.2.6 Immunohistochemistry 
See general materials and methods, section 2.3. 
 
4.2.7 Microscopy 
See general materials and methods, section 2.4. 
 
4.2.8 Quantification of NMJs 
See general materials and methods, section 2.5. 
 
4.2.9 Electrophysiology 
Electrophysiological recordings were obtained with the technical support of 
Derek Thomson. Freshly dissected FDB muscles were used to obtain 
intracellular recordings of evoked endplate potentials (EPPs) and spontaneous 
miniature endplate potentials (mEPPs). FDB muscles were pinned out in a 
Sylgard lined bath (VWR International, Poole, UK) and perfused with 
oxygenated mammalian physiological saline (mM: NaCl 120; KCl 5; CaCl2 2; 
MgCl2 1; NaH2PO4 0.4; NaHCO3 23.8; D-glucose 5.6; bubbled with 5 % CO2/95 % 
O2 mixture.). Muscle contractions were reduced or eliminated by bathing the 
muscles in 2.5µM µ-conotoxin (µ-CTX) GIIIB (Scientific Marketing Associates, 
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UK) for 30–45 min (Gillingwater et al., 2002). 30 muscle fibres per muscle were 
sampled at random using glass microelectrodes filled with 5M potassium 
acetate (impedance ≈ 40 MΩ). Spontaneous and evoked EPPs were recorded 
using Axoclamp 2B amplifiers (Axon Instruments) and stored and analysed on a 
PC using WinWCP v3.9.5 software (developed and distributed by Dr John 
Dempster, Strathclyde University). Average frequency of spontaneous mEPP's 
was obtained from continuous records of 10-60 seconds duration. The quantal 
content was determined from measurements of peak EPP amplitude in trains 
evoked at stimulation frequencies of 0.5-2 Hz, using the variance method with 
correction for non-linear summation implemented in the WinWCP software 
package. 
 
4.2.10 Statistical analysis 
See general materials and methods, section 2.6. 
 
4.2.11 Proteomics 
Unlesioned tibial nerves from nine apoE3 mice and nine apoE4 mice were 
dissected and pooled into 3 groups for each genotype. The same was repeated 
for 9 mice of each genotype 3 weeks after tibial nerve crush injury.  These 
samples underwent iTRAQ proteomic analysis. Nerves were extracted in a 
buffer containing 6 M urea, 2 M thiourea, 2% CHAPS and 0.5% SDS in dH2O. 
The proteins were then precipitated in ice-cold acetone at -20°C overnight. 
Precipitates were pelleted by centrifugation at 13,000 x g for 10 minutes at 4°C. 
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The supernatant was removed and pellets were allowed to air-dry, before being 
resuspended in 6M Urea in 50mM TEAB. 
 
All proteomics experiments were performed at the Keele University Mass 
Spectrometry and Proteomics Facility, Wolfson Centre for Inherited 
Neuromuscular Disease, Oswestry. For detailed proteomics methodology see 
Appendix 8.1.  
 
Tables of changes proteins were analysed at Edinburgh University. Only 
proteins identified with >95% total ion score confidence intervals and by two or 
more unique peptides were accepted as being robust and reliable enough for 
inclusion in further analysis. In order to gain insights into potential pathways 
modified by apoE genotype Ingenuity Pathway Analysis (IPA) software was 
used (Ingenuity Systems). IPA generates networks of proteins, based on ‘hand-
curated’ data held in a database. Specific altered protein interaction networks 
were identified based on the number and percentage of candidate proteins 
contributing to the network. 
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4.3 Results 
 
4.3.1 ApoE genotype has no effect on normal form or function of the mouse PNS.  
Initially, it was important to confirm that apoE was expressed at similar levels in 
the PNS in both the apoE3 and apoE4 mice, to ensure that any differences 
observed were not simply due to differing expression from the transgenes. I 
therefore started by examining apoE expression levels in tibial nerves from mice 
expressing human apoE3 or apoE4 and comparing them to nerves from wild-
type and apoE-/- mice. As expected, apoE protein was undetectable in 
peripheral nerves from wild-type mice and apoE-/- mice, as endogenous apoE 
is only expressed at low levels in the uninjured nervous system (Ignatius et al, 
1986; Skene and Shooter, 1983). However, apoE protein generated from the 
human transgenes (apoE3 and apoE4) was expressed at near-identical levels in 
peripheral nerves from apoE3 and apoE4 mice (Fig. 4.3).  
 
Based on the results of the previous chapter (YFP) it was also important to 
consider how introducing a transgene into these mice could affect any changes 
seen. However, unlike YFP, apoE protein is normally expressed in mice, albeit 
without the polymorphism. Moreover, the majority of the results reported in 
this chapter are from comparisons between apoE3 and apoE4 mice. As both 
mice are expressing a transgene differences seen are more likely to be due to the 
differences between the isoforms of apoE, rather than expression of the 
transgene per se. 
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Once I had established that the transgenes were expressed at similar levels I 
examined peripheral nerves and NMJs from young healthy mice of all four 
genotypes (wild-type, apoE-/-, apoE3 and apoE4) to see if complete removal of 
apoE or expression of the human transgenes had any effect on normal neuronal 
morphology in the PNS. Equivalent numbers of myelinated axon profiles were 
seen in the tibial nerves of mice of each of the genotypes (Fig. 4.4). The majority 
of NMJs (>98%) were fully occupied and mono-innervated (the normal adult 
state) in all genotypes (Fig. 4.5). Therefore no qualitative or quantitative 
differences were observed in the morphological appearance of either the tibial 
nerve or NMJs between mice of each of the different genotypes. 
 
Electrophysiological measurements also suggested normal neuromuscular 
function in mice lacking apoE (apoE-/-) and mice expressing a human transgene 
(in this case apoE4. ApoE3 mice were excluded from this analysis due to 
problems with the breeding colony at the time). Both apoE-/- and apoE4 mice 
had robust EPPs in the flexor digitorum brevis muscle in response to tibial nerve 
stimulation. There was no significant difference in amplitude of EPPs, quantal 
content or rate of spontaneous mEPPs between apoE-/- and apoE4 mice (Fig. 
4.6).  
 
Thus, expression of the human apoE3 or apoE4 isoform had no detrimental 
effect on the form or function of the uninjured mouse PNS.  















Figure 4.3 - ApoE3 and apoE4 isoforms are expressed at equivalent levels in 
unlesioned peripheral nerves from apoE3 and apoE4 transgenic mice. A: 
Representative fluorescent western blot for apoE protein in the uninjured sciatic 
nerve of wild-type (WT), apoE-/- (-/-), apoE3 (E3) and apoE4 (E4) mice, 
showing a lack of apoE in the wild-type and apoE-/- nerves, and comparable 
levels of protein expression in the apoE3 and apoE4 nerves. B: Bar chart 
(mean±SEM) showing quantification of apoE expression levels normalised to 
beta III tubulin (loading control), confirming no difference in expression levels 
between apoE3 and apoE4 (P>0.05 apoE3 vs apoE4; one-way ANOVA with 
Tukey’s post-hoc test; N=3 for each genotype; ns = not significant). 
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Figure 4.4 - Expression of the apoE4 isoform has no effect on normal 
peripheral nerve morphology. A: Representative electron micrographs of cross-
sections from adult sciatic nerves in wild-type (WT), apoE-/- (-/-), apoE3 (E3) 
and apoE4 (E4) mice. All four genotypes had healthy myelinated axon profiles. 
Scale bar = 10µm. B: Bar chart (mean±SEM) showing quantification of 
myelinated axon profiles. There was no significant difference in the number of 
myelinated axons in wild-type, apoE-/-, apoE3 and apoE4 mice (P>0.05; one-
way ANOVA with Tukey’s post-hoc test; wild-type N=3, apoE-/- N=5, apoE3 
N=5, apoE4 N=3). 
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Figure 4.5 - Expression of the apoE4 isoform has no effect on normal 
neuromuscular junction morphology. A: Representative confocal micrographs 
showing immunohistochemically labelled NMJs in LAL muscles showing mono 
innervated, fully occupied endplates in wild-type (WT), apoE-/- (-/-), apoE3 
(E3) and apoE4 (E4) mice (pre-synaptic axons and motor nerve terminals are 
shown in green and post-synaptic acetylcholine receptors labelled with α-
bungarotoxin are shown in red). >98% of NMJs in all muscles examined, 
regardless of genotype, showed this morphology, characteristic of normal 
healthy adult NMJs. Scale bar = 30µm. B: Bar chart (mean±SEM) showing no 
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significant difference in the percentage of fully occupied, mono-innervated 
wild-type, apoE-/-, apoE3 and apoE4 mice (P>0.05; Kruskal-Wallis test with 
Dunn’s post-hoc test; wild-type N=8, apoE-/- N=7, apoE3 N=7, apoE4 N=7). 




Figure 4.6 - Expression of human apoE4 has no effect on normal 
neuromuscular function. A: apoE-/- and apoE4 mice both showed robust EPPs 
in response to tibial nerve stimulation of the flexor digitorum brevis muscle. B: 
Muscles of both genotypes (apoE-/- and apoE4) had EPPs of equivalent 
amplitudes (P>0.05; t-test, two tailed; apoE-/- n=73 fibres N=3 mice, apoE4 
n=75 fibres N=3 mice). C: There was no significant difference in the rate of 
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mEPPs between the genotypes (P>0.05; t-test, two tailed; apoE-/- n=78 fibres 
N=3 mice, apoE4 n=80 fibres N=3 mice).  D: There was no significant difference 
in quantal content between apoE-/- and apoE4 mice (P>0.05; t-test, two tailed; 
apoE-/- n=48 fibres N=3 mice, apoE4 n=32 fibres N=3 mice). 
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4.3.2 ApoE4 expression at physiological levels has no effect on developmental plasticity 
at the NMJ.  
At birth NMJs are innervated by multiple inputs, which are gradually pruned 
back until each NMJ is mono-innervated. This process is known as synaptic 
elimination and in mice is complete by two weeks after birth (Wyatt and Balice-
Gordon, 2003). ApoE4 has previously been shown to modulate synaptic 
plasticity in the CNS (Arendt et al., 1997; Korwek et al., 2009), so I next wanted 
to know whether apoE genotype could influence developmental synaptic 
plasticity in the PNS. I quantified the progression of neonatal synapse 
elimination (for review see Wyatt and Balice-Gordon, 2003) by counting the 
number of axonal inputs to motor endplates at NMJs in the LAL and TA 
muscles of apoE4 and apoE-/- mice at time points over the first two postnatal 
weeks (Fig. 4.7 A/B). ApoE3 mice were omitted from this analysis due to 
problems with the breeding colony at the time. The presence of apoE4 did not 
modify the morphological correlates or time-course of synapse elimination at 
any time-point examined (Fig. 4.7 A-C). Thus, the apoE4 genotype did not 
influence developmental synaptic plasticity. 






















Figure 4.7 - Expression of the apoE4 isoform has no effect on developmental 
plasticity at the NMJ. A/B: Representative confocal micrographs showing 
immunohistochemically labelled NMJs in LAL muscles from apoE-/- (-/-) and 
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apoE4 (E4) mice at postnatal day 3 (A) and 15 (B). Note the presence of poly-
innervated endplates (multiple axons (green) converging on a single motor 
endplate (red)) at P3 (A). Scale bar=30µm. By P15 the process of neonatal 
synapse elimination has remodelled the vast majority of NMJs into the adult 
mono-innervated state (only one incoming axon per endplate) (B). Scale 
bar=30µm C: Bar chart (mean±SEM) showing no significant difference in the 
progression of neonatal synapse elimination in apoE4 mice compared to apoE-/- 
controls at any time-point examined (P>0.05 for all time points; Mann-Whitney 
test, two tailed; P3 apoE-/- N=8, apoE4 N=10; P8 apoE-/- N=12, apoE4 N=20; 
P12 apoE-/- N=4, apoE4 N=25; P15 apoE-/- N=50, apoE4 N=11; ns = not 
significant). 
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4.3.3 ApoE4 expression has no effect on Wallerian degeneration of axons or NMJs 
following peripheral nerve injury.  
ApoE4 has previously been shown to modulate neurodegenerative events in the 
CNS (Horsburgh et al., 2000; Malek et al., 2005; Tesseur et al., 2000), so I next 
asked whether apoE genotype could influence degeneration in the PNS.  
 
I first quantified the extent of Wallerian degeneration occurring at motor nerve 
terminals in the 1st to the 3rd deep lumbrical muscles from wild-type and apoE-/- 
mice after a tibial nerve crush injury in order to find out if loss of apoE had any 
effect on degeneration (Fig. 4.8). To chart the time course of degeneration I 
examined two time points – 18 hours post crush for an intermediate stage of 
degeneration (Fig. 4.8A/B), and 24 hours for late stage of degeneration (Fig. 
4.8C). At this later time point the majority of endplates are vacant in wild-type 
mice so any delay in degeneration would be very obvious (Gillingwater and 
Ribchester, 2001; Miledi and Slater, 1970).  
 
At 18 hours post nerve crush there were significantly fewer vacant (denervated) 
endplates in apoE-/- mice compared to wild-type controls (expressing 
endogenous mouse apoE): only 52.9±3.9% of motor endplates had lost their pre-
synaptic motor nerve terminals in apoE-/- mice compared to 91.5±1.3% in wild-
type mice (Fig. 4.8A/B). However, by 24 hours post-crush almost all motor 
nerve terminals in mice from both genotypes were vacant similar to previous 
descriptions of Wallerian degeneration in wild-type mice (Gillingwater and 
Ribchester, 2001; Miledi and Slater, 1970), showing that the modest delay in 
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degeneration seen at 18 hours post crush was only transient and that the loss of 
apoE did not significantly influence the eventual conclusion of Wallerian 
degeneration. 
 
I next compared degeneration in mice expressing the human apoE3 and apoE4 
transgenes to apoE-/- littermates. Examination of motor nerve terminals at 18 
hours post-crush revealed a subtle but significant increase in the percentage of 
denervated motor endplates in apoE4 muscles compared to apoE-/- muscles 
(Fig. 4.9A). However, the previous observation that loss of apoE delayed 
degeneration at 18 hours compared to wild-type mice (expressing endogenous 
mouse apoE (Fig. 4.8A/B)) suggested that the difference observed between 
apoE4 and apoE-/- mice was caused by the loss of apoE, rather than presence of 
apoE4. In order to further confirm that the apoE4 isoform specifically was not 
influencing Wallerian degeneration, I also compared degeneration rates 
between apoE4 mice and apoE3 mice 18 hours after nerve lesion. No significant 
differences were observed between apoE3 and apoE4 mice (Fig. 4.9A).  
 
As with the wild-type and apoE-/- mice the vast majority of motor endplates in 
apoE3 and apoE4 mice were denervated by 24 hours post nerve crush (Fig. 
4.9B). No significant differences in rate of degeneration were observed between 
any of the genotypes at this time point. 
 
Likewise, Wallerian degeneration of axons in the sciatic nerve 1 week after 
nerve crush occurred at the same rate in apoE3, apoE4 and apoE-/- mice (Fig. 
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4.10). Thus, whilst complete loss of apoE had a very subtle and transient effect 
on the early stages of Wallerian degeneration, neither the apoE3 or apoE4 
transgene had a significant effect on Wallerian degeneration pathways in the 
PNS. 






















Figure 4.8 - Loss of apoE transiently delayed Wallerian degeneration of NMJs 
following peripheral nerve crush injury. A: Representative confocal 
micrographs showing a difference in the morphological appearance of NMJs in 
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apoE-/- (-/-) lumbrical muscles compared to wild-type (WT) controls 18 hours 
after a tibial nerve crush (pre-synaptic axons and motor nerve terminals are 
shown in green and post-synaptic acetylcholine receptors are shown in red). 
Note how all pre-synaptic elements (green) have undergone degeneration in 
wild-type mice whereas some pre-synaptic nerve terminals remain intact in 
apoE-/- mice at 18 hours post crush. Scale bar = 30µm. B: Bar chart showing 
significantly fewer denervated endplates in apoE-/- muscles compared to wild-
type controls 18 hours after tibial nerve crush (P<0.001; Mann-Whitney test, two 
tailed; wild-type n=28 muscles N=5 mice, apoE-/- n=33 muscles N=6 mice). C: 
Bar chart showing no significant difference between the percentage of 
denervated endplates observed in wild-type and apoE-/- mice 24 hours post 
tibial nerve crush (P>0.05; Mann-Whitney test, two tailed; wild-type n=15 
muscles N=4 mice, apoE-/- n=9 muscles N=4 mice). 






















Figure 4.9 - Wallerian degeneration following nerve crush was subtly 
modified by presence of apoE. A: Bar chart (mean±SEM) showing levels of pre-
synaptic degeneration in wild-type, apoE-/-, apoE3 and apoE4 lumbrical 
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muscles, 18 hours after a tibial nerve crush. At this time point significantly more 
endplates in apoE4 muscles were denervated compared to apoE-/- muscles 
(P<0.05; Kruskal-Wallis test with Dunn’s post-hoc). However, there was no 
significant difference in the levels of denervation between apoE3 and apoE4 
mice, indicating that the increase in the rate of degeneration in the apoE4 
compared to apoE-/- mice is more likely to be as a consequence of loss of apoE 
in the apoE-/- mice, rather than and isoform specific effect of apoE4 (P>0.05; 
Kruskal-Wallis test with Dunn’s post-hoc; wild-type N=5, apoE-/- N=6, apoE3 
N=5, apoE4 N=4 mice). B: Bar chart (mean±SEM) showing no significant 
difference between the percentage of denervated endplates observed in wild-
type, apoE-/-, apoE3 and apoE4 lumbrical muscles 24 hours post tibial nerve 
crush (P>0.05; Kruskal-Wallis test with Dunn’s post-hoc test; wild-type N=4, 
apoE-/- N=4, apoE3 N=5, apoE4 N=3 mice). 
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Figure 4.10 - Expression of the apoE4 isoform has no effect on Wallerian 
degeneration of axons following peripheral nerve crush injury. A: 
Representative electron micrographs of cross-sections from adult sciatic nerves 
in apoE-/- (-/-), apoE3 (E3) and apoE4 (E4) mice, 1 week after sciatic nerve 
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crush. Scale bar = 10µm. B: Bar chart (mean±SEM) showing reduced numbers of 
myelinated axons in apoE-/-, apoE3 and apoE4 sciatic nerves 1 week after nerve 
crush injury, but no significant difference in number of myelinated axons 
between the genotypes at either time point. (0 weeks P>0.05; one-way ANOVA 
with Tukey’s post-hoc test; apoE-/- N=5, apoE3 N=5, apoE4 N=3. 1 week 
P>0.05; one-way ANOVA with Tukey’s post-hoc test; apoE-/- N=3, apoE3 N=3 
mice, apoE4 N=2). 
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4.3.4 ApoE4 significantly delays nerve regeneration and neuromuscular reinnervation 
following peripheral nerve injury.  
 
Previous studies reported that complete loss of apoE did not affect regeneration 
of peripheral axons following nerve injury (Genden et al., 2002; Popko et al., 
1993). To confirm and extend these findings to include functional reinnervation, 
I examined NMJs in deep lumbrical muscles from apoE-/- and wild-type mice 
following tibial nerve crush. As expected, there was no significant difference in 
the levels of NMJ reinnervation between apoE-/- and wild-type control mice at 
2 or 3 weeks post nerve crush (Fig. 4.11). These data therefore support the 
findings of previous studies (Genden et al., 2002; Popko et al., 1993) and suggest 
that apoE per se is not essential for nerve regeneration and subsequent 
reinnervation of NMJs.  
 
However, the more biologically relevant question is whether apoE genotype can 
influence regeneration and subsequent functional reinnervation in the PNS 
following nerve crush injury. I therefore used electron microscopy to quantify 
axon regeneration in the sciatic nerve of apoE3 and apoE4 mice at 2 and 3 weeks 
following sciatic nerve injury (Fig. 4.12). At one week post-injury (the time when 
regeneration is beginning following Wallerian degeneration in vivo: see above) 
there was no difference in the number of axons in the sciatic nerves of apoE3 
and apoE4 mice. However, at 2 weeks post-injury, apoE4 mice showed 
significantly reduced numbers of regenerating axons in the sciatic nerve 
compared to apoE3 mice (only 63% regeneration when compared with apoE3 
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mice, P<0.05; fig 4.12). This significant delay in regeneration persisted in apoE4 
mice 3 weeks after injury, where regeneration was almost complete in apoE3 
mice, but had only reached 70% of these levels in apoE4 mice (P<0.05; Fig. 4.12). 
 
To confirm that the delay in axon regeneration in apoE4 mice also resulted in 
delayed reinnervation of peripheral targets by the regenerating axons, I then 
quantified reinnervation of NMJs in the lumbrical muscles (innervated by the 
tibial nerve) of apoE3 and apoE4 mice following tibial nerve injury. 2 weeks 
after nerve injury, lumbrical muscles in apoE4 mice had significantly fewer 
reinnervated endplates compared to both apoE3 mice and apoE-/- mice (32% 
reinnervation compared with apoE3 mice, P<0.001; Fig. 4.13). 
 
As expected, the reinnervation process progressed in both apoE-/- and apoE4 
muscles between two (Fig. 4.13) and three (Fig. 4.14) weeks post crush, 
manifesting as an increase in the numbers of reinnervated endplates. However, 
neuromuscular reinnervation was still significantly delayed in apoE4 mice 
compared to apoE-/- controls three weeks after tibial nerve crush (Fig. 4.14).  
 
Surprisingly, however, reinnervation did not appear to progress at all between 
the two and three week time-points in apoE3 mice (~65% of endplates were 
reinnervated at both 2 and 3 weeks after nerve crush; Fig. 4.13B and Fig. 4.14). 
As a result, the enhanced levels of reinnervation observed in these mice at 2 
weeks were lost, leaving a significantly reduced number of reinnervated NMJs 
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compared to apoE-/- mice, with levels comparable to those observed in apoE4 
mice.   
 
To be sure that the delay in axon regeneration and neuromuscular reinnervation 
observed in apoE4 mice was not occurring due to differing expression levels of 
human apoE transgenes after nerve injury I used fluorescent quantitative 
western blotting to measure the levels of apoE protein in tibial nerves from 
apoE3 and apoE4 mice two weeks after nerve crush (Fig. 4.15). Expression levels 
of apoE protein were identical in apoE3 and apoE4 nerves. As expected there 
was no expression of apoE in the apoE-/- mice, and an up-regulation of the 
protein in the injured wild-type nerves (Fig. 4.3A compared to Fig. 4.15A). 
 
Taken together, these data show that apoE4 selectively delays nerve 
regeneration and subsequent neuromuscular reinnervation in the PNS. 




Figure 4.11 - Complete loss of apoE has no effect on neuromuscular 
reinnervation following nerve crush injury. A/B: Representative confocal 
micrographs showing fully reinnervated endplates in immunohistochemically 
labelled wild-type (A) and apoE-/- (B) lumbrical muscles three weeks after a 
tibial nerve crush. Scale bar = 30µm. C: Bar chart (mean±SEM) showing no 
significant difference in the level of neuromuscular reinnervation in lumbrical 
muscles from apoE -/- mice compared to wild-type controls two weeks after a 
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tibial nerve crush (P>0.05; Mann-Whitney test, two tailed; wild-type N=5 mice, 
apoE-/- N=6 mice). D: Bar chart showing no significant difference in the level of 
neuromuscular reinnervation in lumbrical muscles from apoE -/- mice 
compared to wild-type controls three weeks after a tibial nerve crush (P>0.05; 
Mann-Whitney test, two tailed; wild-type N=8, apoE-/- N=12 mice).  
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Figure 4.12 – The apoE4 isoform significantly delays nerve regeneration 
following sciatic nerve injury. A: Representative electron micrographs showing 
cross-sections from adult sciatic nerves in apoE3 (E3) and apoE4 (E4) mice, one, 
two and three weeks after sciatic nerve crush. Scale bar = 10µm. B: Scatter plot 
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(mean±SEM) showing time course of axonal regeneration in apoE3 and apoE4 
sciatic nerves following sciatic nerve crush. At both two and three weeks post-
crush apoE4 significantly delays regeneration (63% and 70% that of the levels of 
apoE3 axon regeneration at the same time points, respectively; 1 week P>0.05; t-
test, two-tailed; apoE3 N=3, apoE4 N=2; 2 weeks P<0.05; t-test, two-tailed; 
apoE3 N=6 apoE4 N=6. 3 weeks P<0.05; t-test, two-tailed; apoE3 N=11, apoE4 
N=11). 
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Figure 4.13 - ApoE4 significantly delays neuromuscular reinnervation 
following tibial nerve crush injury. A: Representative confocal micrographs 
showing NMJs from apoE-/-, apoE3 and apoE4 lumbrical muscles two weeks 
after a tibial nerve crush (pre-synaptic axons and motor nerve terminals shown 
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in green and post-synaptic acetylcholine receptors labelled with α-bungarotoxin 
are shown in red). Note how all endplates in the field of view in the apoE-/- and 
apoE3 muscles have been reinnervated, whereas in the apoE4 muscle some 
endplates are still awaiting reinnervation (white arrowheads). Scale bar = 30µm. 
B: Bar chart (mean±SEM) showing levels of neuromuscular reinnervation in 
lumbrical muscles 2 weeks after a tibial nerve crush. Reinnervation was 
significantly delayed in apoE4 mice compared to both apoE-/- and apoE3 mice 
(P<0.01 and P<0.001 respectively; Kruskal Wallis test with Dunn’s post-hoc test; 
apoE-/- N=6, apoE3 N=5, apoE4 N=5).  















Figure 4.14 - ApoE4 significantly delays neuromuscular reinnervation 
following nerve crush injury in the mouse PNS. Bar chart showing levels of 
reinnervation in lumbrical muscles 3 weeks after a tibial nerve crush. 
Neuromuscular reinnervation was still significantly delayed in apoE4 muscles 
compared to apoE-/- muscles. (P<0.001; Mann-Whitney test, two tailed; apoE-/- 
n=63 muscles N=12 mice, apoE4 n=34 muscles N=6 mice). 
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Figure 4.15 – The delayed axon regeneration and neuromuscular reinnervation 
seen in apoE4 mice is a specific response to the E4 isoform of apoE, and is not 
due to differing expression levels from human apoE transgenes after nerve 
injury. A: Representative fluorescent Western blots showing levels of apoE and 
tubulin (loading control) protein extracted from sciatic nerves 3 weeks after 
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nerve injury. There is no obvious difference in the levels of apoE protein 
expression between apoE3 and apoE4 isoforms. B:  Bar chart (mean±SEM) 
showing quantification of Western blots, confirming no difference in the levels 
of apoE3 and apoE4 protein expressed in distal nerve stumps (N=2 per 
genotype). 
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4.3.5 ApoE genotype modifies expression levels of proteins associated with cellular 
outgrowth and blood-nerve barrier integrity in peripheral nerve in vivo.  
Given the finding that apoE genotype modifies nerve regeneration in the mouse 
PNS in vivo, I next wanted to identify potential molecular mechanisms 
underlying the genotype specific response. To do this I first used iTRAQ 
proteomics to compare protein expression levels in tibial nerves from apoE3 and 
apoE4 mice. As these were uninjured nerves these experiments were designed 
to pick up any changes in the peripheral nerve proteome occurring solely as a 
result of the presence of different isoforms of apoE, in the absence of any 
external stimuli (e.g. nerve degeneration or regeneration following nerve crush 
injury). The peripheral nerve preparations used were whole nerves, so 
contained all cell types present in the peripheral nerve (glial cells, capillaries, 
extracellular matrix etc.) as well as axons. These cell types make up the local 
microenvironment, which needs to be conducive for nerve regeneration to 
occur, so was important to consider in this experiment. 
 
Using stringent inclusion criteria (see Materials and methods, 4.2.11), 62 
proteins showed expression levels increased >20% in uninjured apoE4 
peripheral nerves compared to apoE3 peripheral nerves (Table 4.1), and 40 
proteins had expression levels decreased >20% in peripheral nerves in the 
apoE4 mice (Table 4.2). Neither of the protein products from the apoE3 or apoE4 
transgenes were picked up as they are human proteins and the analysis was set 
to identify mouse proteins.  
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Proteins identified with differing expression levels were then analysed using 
Ingenuity Pathway Analysis software to look for potential clustering of 
functions or interactions. Systems level analysis of protein expression changes 
highlighted interaction networks of myosin and actin proteins, associated with 
regulation of tissue and cell morphology (Fig. 4.16). Networks associated with 
haematological regulation, including the integrity of the blood brain barrier 
(BBB) and blood nerve barrier (BNB) were also identified as being changed in 
the apoE4 mice compared to apoE3 (Fig. 4.17). These data show that even in 
normal healthy nerve, expression of the different apoE isoforms can lead to 
significant modifications in the peripheral nerve proteome, likely to have 
implications for form and function. 
 
Within the myosin/actin interaction network there were changes in several 
myosin proteins in the uninjured peripheral nerve in apoE4 mice, in the absence 
of any corresponding changes in actin. Myosin proteins within these 
myosin/actin networks are essential for neurite outgrowth and as molecular 
motors are responsible for transporting actin to parts of the cell where it is 
needed for cell growth (Brown and Bridgman 2003; Chantler and Wylie, 2003; 
Wylie et al., 1998). However, corresponding changes in levels of actins would be 
necessary for the pathway to lead to alterations in cell morphology in uninjured 
nerves (Arnold 2009; Brown and Bridgman 2004; Chantler and Wylie, 2003). 
This finding was therefore consistent with the earlier morphological data 
showing that expression of apoE4 does not affect the form or function of the 
uninjured PNS in vivo (see section 4.3.1, and Figs. 4.4 and 4.5). These changes in 
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levels of myosin proteins in the uninjured nerve may however represent a 
‘priming’ response, which has no effect on the healthy PNS, but could result in a 
change in actin dynamics following nerve injury.  
 
To test whether changes in myosin levels lead to corresponding changes in actin 
levels in the regenerating peripheral nerve the iTRAQ proteomics experiments 
were repeated using nerves from apoE3 and apoE4 mice 3 weeks after sciatic 
nerve crush injury. As in the experiments on uninjured nerves, large numbers of 
proteins had altered expression levels in the apoE4 regenerating nerves 
compared to the apoE3 nerves. 28 proteins showed increased expression levels 
>20% in regenerating peripheral nerves from apoE4 mice compared to apoE3 
peripheral nerve (Table 4.3), and 81 proteins had decreased expression levels 
>20% in regenerating apoE4 peripheral nerves (Table 4.4). Many of the proteins 
altered in the regenerating nerves were similar to those identified in the 
uninjured nerves, such as the proteins involved in haematological regulation, 
e.g. orosomucoid 1 and haptoglobin. However, even more dramatic changes 
were seen in the expression levels of both myosin and actin proteins in the 
apoE4 regenerating nerves  (Table 4.4). The proteins altered in the regenerating 
nerves were also analysed using Ingenuity Pathway Analysis software to look 
for potential clustering of functions or interactions. 71% of the proteins in a 
myosin / actin network had altered levels of expression in the uninjured nerves 
(Fig. 4.16), whereas 83% and 86% of proteins in two separate myosin / actin 
networks had altered expression levels in the regenerating apoE4 nerves (Fig. 
4.18 and 4.19). 
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The myosin/actin pathways are key pathways for cellular reorganisation in 
processes such as nerve regeneration following nerve injury (Arnold, 2009; 
Brown and Bridgman, 2004; Chantler and Wylie, 2003). The reduction in the 
levels of so many of these proteins in apoE4 peripheral nerve compared to 
apoE3 is therefore likely to be playing a significant role in reducing the 
regenerative capacity of these mice following nerve injury. 
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Figure 4.16 - Modification of myosin and actin protein interaction pathways 
in uninjured apoE4 peripheral nerves. Protein interaction network (generated 
by Ingenuity Pathway Analysis) showing interactions of myosin and actin 
proteins involved in regulation of tissue and cell morphology. 71% of proteins  
had modified expression levels in apoE4 uninjured peripheral nerves compared 
to apoE3 tissue (green = up in apoE4 vs apoE3; red = down in apoE4 vs apoE3; 
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grey = unchanged). Solid connecting lines indicate the presence of a direct 
interaction and dashed connecting lines indicate an indirect interaction.  
 
Key to proteins - Actin; calcineurin proteins; CALD1 – h-caldesmon; CKM – 
muscle creatine kinase; CNN1 – h1-calponin alpha; CNP - 2',3'-cyclic nucleotide 
3' phosphodiesterase isoform 2; DSTN – destrin isoform CRA_b; ERK1/2 – 
extracellular signal-regulated kinase; F Actin – filamentous actin; FHL1 - 
skeletal muscle LIM protein; FLNA - filamin alpha; HSPB6 - heat shock protein, 
alpha-crystallin-related, B6; LPP - LIM domain containing preferred 
translocation partner in lipoma isoform 1; MB – myoglobin; MEF2 – myocyte 
enhancer factor 2; MFGE8 - milk fat globule-EGF factor 8 protein isoform 2; 
MLC - mKIAA0777 protein; MYH4 - myosin, heavy polypeptide 4, skeletal 
muscle; MYH6 - alpha cardiac myosin heavy chain; MYH7 - Myh7 protein; 
MYH8 - myosin, heavy polypeptide 8, skeletal muscle, perinatal; MYL1 - fast 
skeletal myosin alkali light chain 1 isoform 1f; MYL3 - myosin, light polypeptide 
3, isoform CRA_a; MYL6B - myosin, light polypeptide 6B;  MYL9 (includes 
EG:98932) - myosin regulatory light polypeptide 9; Myosin - Myosin-binding 
protein C, fast-type; Nfat family – nuclear factor of activated T-cells; P38 MAPK  
- P38 mitogen-activated kinase; PDGF BB – platelet-derived growth factor beta 
polypeptide; Pkc(s) – protein kinase C; PVABL – parvalbumin; S100A9 - S100 
calcium binding protein A9 (calgranulin B); TAGLN – transgelin; Tgf beta – 
transforming growth factor beta; TNNT3 - troponin T. 
 
 




Figure 4.17 - Modification of protein interaction pathways involved with 
haematological regulation in uninjured apoE4 peripheral nerves Protein 
interaction network (generated by Ingenuity Pathway Analysis) showing 
interactions of proteins involved in haematological regulation (including 
integrity of the blood-brain/blood-nerve barrier). 91% of proteins had modified 
expression levels in apoE4 uninjured peripheral nerves compared to apoE3 
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tissue (green = up in apoE4 vs apoE3; red = down in apoE4 vs apoE3; grey = 
unchanged). Solid connecting lines indicate the presence of a direct interaction 
and dashed connecting lines indicate an indirect interaction.  
 
Key to proteins - ACTN2* - actinin alpha 2; ACTN3 - actinin alpha 3; ALB - 
albumin precursor; Alpha Actinin - Actinin alpha 2; ATP2A1 - ATPase, Ca++ 
transporting, cardiac muscle, fast twitch 1, isoform CRA_c; ATP2A2 - ATPase, 
Ca++ transporting, slow twitch 2 isoform a; ATP2A3 (aka SERCA); Ca2 ATPase 
– ATPase, Ca++ transporting, ubiquitous; CFD - adipsin precursor; CLU - 
clusterin precursor; COL1A2 - procollagen, type I, alpha 2 precursor; 
Collagen(s) - Collagen alpha-1(XIV) chain; Ferritin; FGA - fibrinogen, alpha 
polypeptide, isoform CRA_b; FGB - fibrinogen beta chain precursor; FGG - 
fibrinogen, gamma polypeptide; Fibrin; Fibrinogen; HBA1 - haemoglobin 
alpha, adult chain 2; HBB (includes EG:3043) - haemoglobin, beta adult major 
chain; Haemoglobin; HP - haptoglobin precursor; HPX - hemopexin precursor; 
LDB3 - LIM domain binding 3 isoform b; Ldh - lactate dehydrogenase; LDHA - 
lactate dehydrogenase A isoform 1; MYH11 - myosin, heavy chain 11, smooth 
muscle; NFkB (complex) - nuclear factor of kappa light polypeptide gene 
enhancer in B-cells; PDLIM3 - PDZ and LIM domain protein 3; SERCA – (aka 
ATP2A3); SORBS2 - mKIAA0777 protein; Stat3-Stat3 - signal transducer and 
activator of transcription 3; T3-TR-RXR – thyroid hormone receptor/retinoid X 
receptor heterodimer; TTN – titin; XDH - xanthine dehydrogenase. 
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Figure 4.18 - Modification of actin protein interaction pathways in 
regenerating apoE4 nerves 3 weeks after nerve crush injury. Protein 
interaction network (generated by Ingenuity Pathway Analysis) showing 
interactions of proteins involved in actin-based regulation of tissue and cell 
morphology. 83% of proteins had modified expression levels in regenerating 
	   139	  
apoE4 peripheral nerves compared to apoE3 tissue. (green = up in apoE4 vs 
apoE3; red = down in apoE4 vs apoE3; grey = unchanged). Solid connecting 
lines indicate the presence of a direct interaction and dashed connecting lines 
indicate an indirect interaction.  
 
Key to proteins - ACTA1 - actin, alpha 1, skeletal muscle; ACTA2 - alpha 2 
actin; ACTN1* - actinin, alpha 1; ACTN2* - actinin alpha 2; ACTN3 - actinin 
alpha 3; Alpha Actinin - Actinin alpha 2; ATP2A1 - ATPase, Ca++ transporting, 
cardiac muscle, fast twitch 1, isoform CRA_c; ATP2A2 - ATPase, Ca++ 
transporting, slow twitch 2 isoform a; ATP2A3 - ATPase, Ca++ transporting, 
ubiquitous; Ca2 ATPase; Calmodulin; Calpain; CaMKII; CAMK2A - 
calcium/calmodulin-dependent protein kinase II alpha isoform 1; CAPNS1 - 
calpain small subunit; CNP - 2',3'-cyclic nucleotide 3' phosphodiesterase isoform 
2; ERK1/2 - extracellular signal-regulated kinase; F Actin; Fascin; FLNA - 
filamin, alpha; Focal adhesion kinase; G-Actin; HPX- hemopexin precursor; 
LDB3* - LIM domain binding 3 isoform b; MAP6 - microtubule-associated 
protein 6 isoform 1; MFGE8 - milk fat globule-EGF factor 8 protein isoform 2; 
MYOZ1  - myozenin 1; NEB – nebulin; PDLIM3 - PDZ and LIM domain protein 
3; Pmca - plasma membrane Ca2+ ATPase; SERCA; TPM1* - tropomyosin 1, 
alpha isoform I; TPM2 - tropomyosin 1, alpha, isoform CRA_b; TTN – titin. 




Figure 4.19 - Modification of actin and myosin protein interaction pathways 
in regenerating apoE4 nerves 3 weeks after nerve crush injury. Protein 
interaction network (generated by Ingenuity Pathway Analysis) showing 
interactions of proteins involved in actin/myosin-based regulation of tissue and 
cell morphology. 86% of proteins had modified expression levels in regenerating 
apoE4 peripheral nerves compared to apoE3 tissue (green = up in apoE4 vs 
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apoE3; red = down in apoE4 vs apoE3; grey = unchanged). Solid connecting 
lines indicate the presence of a direct interaction and dashed connecting lines 
indicate an indirect interaction.  
 
Key to proteins in fig 4.19 - Actin; Alpha actin - actin, alpha 1, skeletal muscle; 
calcineurin proteins; CKM - muscle creatine kinase; CKMT1B - creatine kinase, 
mitochondrial 1, ubiquitous, isoform CRA_c; CKMT2; Collagen(s); Creatine 
Kinase; FGA - fibrinogen, alpha polypeptide, isoform CRA_b; FGB - fibrinogen 
beta chain precursor; FGG - fibrinogen, gamma polypeptide; Fibrin; 
Fibrinogen; MB – myoglobin; MEF2 - myocyte enhancer factor 2; MYH1 - 
myosin, heavy polypeptide 1, skeletal muscle, adult; MYH2 - myosin heavy 
chain IIa; MYH4 - myosin, heavy polypeptide 4, skeletal muscle; MYH6 - 
myosin, heavy polypeptide 6, skeletal muscle; MYH7 - Myh7 protein; MYH8* - 
myosin, heavy polypeptide 8, skeletal muscle, perinatal; MYH11 - myosin, 
heavy polypeptide 11, skeletal muscle; MYL1 - myosin, light polypeptide 1; 
MYL3 - myosin, light polypeptide 3, isoform CRA_a; MYLK - Myosin, light 
polypeptide kinase; MYLPF - myosin light chain, phosphorylatable, fast skeletal 
muscle; Myosin; Myosin2; NFkB (complex) - nuclear factor of kappa light 
polypeptide gene enhancer in B-cells; NID1 – nidogen 1 precursor; PVALB – 
parvalbumin; Shc - Src homology 2 domain containing) transforming protein 1; 
Stat3-Stat3 - signal transducer and activator of transcription 3; Tropomyosin - 
tropomyosin 1, alpha isoform I. 
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4.4 Discussion 
In this chapter I have shown an apoE genotype-dependent regulation of nerve 
regeneration in the PNS in vivo. I have shown that the presence of the apoE4 
isoform selectively delays peripheral nerve regeneration and neuromuscular 
reinnervation, in the absence of any effect on normal form or function. 
Comparative iTRAQ proteomics revealed significant changes in the proteome of 
apoE4 peripheral nerve compared to that in apoE3 mice, both before and after 
nerve crush. Proteins associated with the regulation of cellular outgrowth and 
regeneration (myosin / actin pathways) and haematological regulation have 
modified expression levels in apoE4 peripheral nerves compared to apoE3.  
 
The most notable finding in this study is the impaired axonal regeneration and 
neuromuscular reinnervation following peripheral nerve injury in apoE4 mice. 
This finding is in agreement with previous in vitro studies on cultured dorsal 
root ganglia and hippocampal neurons. In these studies the neuronal cell lines 
were incubated with a lipid source and either apoE3 or apoE4. The cells 
incubated with apoE3 showed increased levels of neurite outgrowth, whereas 
cells incubated with apoE4 had reduced levels of neurite outgrowth (Bellosta et 
al., 1995; Nathan et al., 1994; Teter et al., 2002). Bellosta and colleagues also 
showed that this effect was dose dependent: increasing E3 levels lead to 
increased sprouting, whereas increasing E4 decreased levels of sprouting 
(Bellosta et al., 1995). 
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The finding that a complete loss of apoE did not affect regeneration in the PNS 
is also in agreement with previous studies which showed no influence of loss of 
apoE on peripheral nerve regeneration (Genden et al., 2002; Popko et al., 1993). 
This has also been shown in the CNS; following a lesion in the entorhinal cortex 
both wild-type and apoE-/- mice showed similar levels of synaptic remodelling 
(Anderson et al., 1998). As apoE is one of several lipoproteins in the nervous 
system it has been hypothesised that other apolipoproteins could functionally 
compensate for a loss of apoE in the apoE-/- mice, leading to a null result in 
these regeneration studies (Anderson et al., 1998). In contrast, my results 
showed that complete loss of apoE did subtly affect the process of Wallerian 
degeneration following nerve injury, transiently reducing the rate compared to 
mice expressing apoE. This effect was subtle and did not persist beyond 18 
hours, but suggests that apoE, which is up-regulated quickly following nerve 
injury (Ignatius et al., 1986; Skene and Shooter, 1983), can influence early stages 
of Wallerian degeneration, although its absence is not sufficient to delay the 
process by more than a few hours. 
 
One slightly puzzling result from this study was the time course of 
neuromuscular reinnervation in the apoE3 mice following tibial nerve crush. 
ApoE3 significantly enhanced the initial stages of reinnervation, in agreement 
with the previous studies showing that it significantly enhances neurite 
outgrowth in vitro (Bellosta et al., 1995; Nathan et al., 1994; Teter et al., 2002). 
However, while both the apoE-/- and apoE4 mice had an increase in the 
percentage of reinnervated endplates between 2 and 3 weeks post nerve crush, 
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reinnervation of NMJs in the apoE3 mice failed to progress despite an increase 
in regenerating axons (see Fig. 4.12). One possible explanation for this NMJ 
specific phenotype is that apoE3 alters the process of synaptic pruning that 
follows reinnervation at the NMJ. This would mean that endplates in apoE3 
mice could be left in a poly-innervated state for longer than those in apoE-/- or 
apoE4 mice, which would mean that they would not be counted as being fully 
reinnervated, and thus lead to a lower percentage of reinnervated endplates in 
the apoE3 mice. This hypothesis is supported by a previous study by White and 
colleagues showing that apoE genotype can modulate synaptic plasticity in vivo 
(White et al., 2001), and is worthy of future study.  
 
The reduced regenerative capacity of peripheral nerves in the apoE4 mice 
provides a possible explanation for several human cohort studies that have 
reported associations between the apoE4 genotype and poor prognosis in a 
number of PNS diseases. Both diabetic and HIV-associated neuropathies have 
been reported to have a higher frequency in individuals possessing the apoE4 
allele (Bedlack et al., 2003; Corder et al., 1998; Tsuzuki et al., 1998). A number of 
human cohort studies have examined a potential relationship between apoE 
genotype and motor neuron disease, with conflicting results (Al-Chalabi et al, 
1996; Bachus et al, 1997; Drory et al, 2001; Li et al, 2004b; Moulard et al, 1996; 
Mui et al, 1995; Siddique et al, 1998; Smith et al, 1996). Motor neuron 
regeneration is known to play an important role in motor neuron diseases such 
as ALS: as some motor neurons degenerate other, compensatory motor neurons 
sprout new branches in an attempt to reinnervate vacated endplates and thus 
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prolong muscle function (Schaefer et al., 2005).  The finding that apoE4 impairs 
axonal regeneration and reinnervation therefore suggests that apoE genotype 
could impact on disease progression, as neurons in apoE4 patients would have 
reduced capacity for axonal sprouting and reinnervation. This could provide an 
explanation for those studies reporting an association between apoE-genotype 
and disease progression (Al-Chalabi et al, 1996; Drory et al, 2001; Li et al, 2004; 
Moulard et al, 1996). Clinically, the knowledge of an individual’s apoE genotype 
could therefore provide insights into the likely success of regeneration following 
peripheral nerve trauma or disease, and lead to a more accurate, patient-
specific, prognosis.  
 
The proteomic experiments revealed widespread changes in the proteome of the 
peripheral nerves of apoE4 mice, both before and after nerve injury. In 
uninjured nerves apoE4 mice had altered expression levels of a range of myosin 
isoforms, and of proteins associated with regulation of the blood-nerve barrier. 
As these changes were found in normal, healthy, uninjured nerves it is possible 
to conclude that they were occurring as a direct result of the apoE genotype, 
rather than as a result of altered nerve regeneration. The three weeks post injury 
time point was chosen in order to analyse the protein expression levels of apoE3 
and apoE4 nerves during the course of regeneration. At this time point changed 
expression levels of both myosin and actin proteins were found in the apoE4 
nerves compared to the apoE3 nerves.  
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Actin is a major component of the cytoskeleton, and has been shown to be up-
regulated following nerve injury. Its role as a modulator of cell morphology and 
outgrowth of neurons is well established (Arnold, 2009; Letourneau, 2009; 
McQuarrie and Lund, 2009; Tetzlaff et al., 1988).  However, more recent work 
has shown that myosin is also involved in the regeneration process in nerves, 
and that interactions between myosin and actin proteins in neurons are 
necessary for successful nerve regeneration. Although myosin is more 
commonly thought of in connection with its role in muscle contraction many 
myosin isoforms have been found to be present in both the axonal and synaptic 
compartments of neurons (Bearer et al., 1993; Brown and Bridgeman, 2004; 
Vega-Riveroll et a., 2005). Myosin has been shown to drive neurite outgrowth in 
vitro (Wylie et al., 1998) and to have a role in regulating axonal path finding 
during development (Ma et al., 2006; Zhu et al., 2007). Similar to apoE, myosin 
Va is up-regulated in a time dependant manner at the site of injury (Calliari et 
al., 2002), and is essential for the transport of neurofilaments in neurons (Alami 
et al., 2009; Rao et al., 2002; Schaefer et al 2008). Given the importance of actin / 
myosin pathways in nerve regeneration the widespread changes in expression 
levels of these proteins in apoE4 peripheral nerves may contribute to the 
reduced regenerative capacity seen in the apoE4 mice. Further work is now 
needed to investigate the roles that specific myosin and actin proteins are 
playing in the apoE genotype-dependent regeneration of peripheral nerves. 
 
In addition to the changes in the myosin / actin pathways, the proteomics 
experiments also revealed expression level changes in proteins associated with 
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haematological regulation in the apoE4 peripheral nerves, several of which are 
important in maintaining the integrity of the blood-brain barrier (BBB) and 
blood-nerve barrier (BNB). Previous studies using apoE-/- mice have shown 
that loss of apoE impairs both the BBB and the BNB (Fullerton et al., 2001; 
Methia et al., 2001). These studies both used Evan’s blue dye to measure the 
levels of extravasation, and showed that in the absence of apoE the BBB and 
BNB become more leaky. More recently Nishitsuji and colleagues have 
investigated the effects of the apoE3 and apoE4 isoforms on the properties of the 
BBB in vitro (Nishitsuji et al. 2011). They showed that the function of the tight 
junctions between endothelial cells is impaired in cultures from apoE4 mice 
compared to wild-type or apoE3, leading to a greater permeability of the BBB in 
apoE4 (Nishitsuji et al. 2011). In my proteomics experiments Orosomucoid I, a 
protein which has been shown to modulate the permeability of the BBB (Yuan et 
al., 2010), was found to be up-regulated in both uninjured and regenerating 
apoE4 nerves. Another protein found to be up-regulated in apoE4 nerves was 
fibrinogen, which is known to leak into the CNS immediately following BBB 
disruption, a play a role in mediating neuronal damage (Schachtrup et al., 2010). 
Changes in expression levels of these proteins in the apoE4 mice provide 
potential molecular mechanisms through which the apoE4 genotype may be 
modulating the haematological regulation of the nervous system. Although it is 
not possible to link this directly to the reduced capacity for regeneration in the 
apoE4 mice, Previtali and colleagues have previously reported that nerve 
regeneration is impaired in the presence of breaches of the BNB in human sural 
nerves (Previtali et al., 2008). Further work is now needed to discover if any of 
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the proteins found altered in the PNS also have modified expression levels in 
the CNS, and if they are affecting the integrity of the BBB in an apoE-genotype 
specific manner.  
 
In summary I have shown that apoE genotype significantly modifies the 
regenerative capacity of the PNS in vivo, with the apoE4 genotype giving rise to 
attenuated regeneration and reinnervation following nerve injury. Comparative 
proteomics experiments revealed concomitant changes in the proteome of 
peripheral nerve in apoE4 mice, which are likely to affect the form and function 
of the PNS, and are worthy of future study.  
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Chapter 5 - ERCC1 
 
5.1 Introduction 
DNA contains the blueprint for the normal functioning of every organism. 
However, the fundamental problem with DNA is that it is not chemically inert, 
and damage to DNA can alter its coding properties or transcription (Martin, 
2008). DNA damage has been linked to carcinogenesis, aging and a number of 
genetic disorders (de Boer and Hoeijmakers, 2000; Schumacher et al., 2008). 
 
Alterations to the structure of DNA can occur spontaneously due to intrinsic 
instability of the chemical bonds within DNA, or be caused by endogenous 
metabolic products (de Boer and Hoeijmakers, 2000; Lindahl, 1993). Exogenous 
environmental factors, such as ultraviolet radiation or chemical compounds in 
cigarette smoke, can also cause DNA damage (Cleaver, 1968; Pfeifer et al., 2002). 
DNA damage occurs in many forms, such as single- and double-strand breaks, 
inter- and intrastrand crosslinks and base modifications (de Boer and 
Hoeijmakers, 2000). 
 
Several DNA repair strategies have evolved to fix damage to DNA and prevent 
it from having detrimental consequences for the organism. Different repair 
pathways act on different forms of damage, although there is a lot of overlap 
and many proteins are involved in more than one pathway (Lindahl et al., 1997). 
The main DNA repair mechanisms are base excision repair (BER), nucleotide 
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excision repair (NER), mismatch repair (MMR), and recombinational repair (for 
review see Jeppesen et al., 2011). BER removes single incorrect or damaged 
bases from DNA by breaking the base-sugar bond holding them in place, and 
replacing them (for review see David et al., 2007).  NER removes bulky DNA 
distorting lesions, most commonly caused by UV radiation (for review see 
Niedernhofer, 2008). MMR is responsible for maintaining the accuracy of DNA 
replication by targeting incorrect bases which arise from replication errors (for 
review see Hsieh and Yamane, 2008). Recombinational repair mends single and 
double strand cross breaks by homologous recombination (for review see 
Kuzminov, 1999). 
 
Deficiencies in any of the DNA repair pathways lead to genomic instability and 
can have severe consequences (Jeppesen et al., 2011). Several hereditary DNA 
repair deficiency disorders are associated with an increased risk of cancer. The 
link between compromised DNA repair and cancer was first established in 1968 
by James Cleaver, who noticed that fibroblasts from patients with xeroderma 
pigmentosum (XP), a hereditary disease characterised by extreme 
photosensitivity and skin cancer, had defects in DNA repair following UV 
exposure (Cleaver, 1968). This study also connected DNA repair and 
neurodegeneration, as approximately 30% of patients with XP have neurological 
symptoms including microcephaly, ataxia, loss of reflexes and 
neurodegeneration with peripheral neuropathy (Kraemer et al., 2007; Rass et al., 
2007). 
 
	   151	  
As post-mitotic, terminally differentiated cells, neurons are thought to be 
particularly vulnerable to accumulating DNA lesions throughout life (de Waard 
et al., 2010). The number of DNA repair deficiency disorders that are 
characterised by neurodegeneration and neuropathological changes highlights 
this vulnerability (Barzilai et al., 2008). Neurons are also highly metabolically 
active, generating large quantities of reactive oxygen species (ROS) with the 
capacity to damage DNA (Halliwell, 2006; McKinnon, 2009). 
 
It is thought that different regions of the brain are differentially affected by 
DNA repair defects (Barzilai et al., 2008). The cerebellum is particularly 
susceptible: diseases such as ataxia telangiectasia and spinocerebellar ataxia 
with axonal neuropathy 1 are caused by mutations that affect the repair of 
single- and double-strand breaks, and profoundly affect the cerebellum 
(McKinnon, 2009). However, the effect of DNA damage in the PNS and the role 
or DNA damage repair in maintaining motor neurons is not fully understood 
(de Waard et al., 2010). 
 
Here I have investigated the effect of failure to repair DNA damage at the NMJ 
(which is known to be an early pathological target in many diseases; Wishart et 
al., 2006), using a strain of mouse with a mutation in the ERCC1 gene. ERCC1 is 
primarily involved in the nucleotide excision repair pathway (NER), but also 
plays a role in repairing some double strand breaks and interstrand crosslinks 
(Ahmad et al., 2008; Bergstralh and Sekelsky, 2008; Gregg et al., 2011). ERCC1 
functions as part of a heterodimer with xeroderma pigmentosum group F (XPF), 
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severing damaged DNA 5’ to lesions identified in the NER pathway 
(Niedernhofer, 2008; Wood, 
 2010). Mutations in either ERCC1 or XPF give rise to a variety of conditions 
characterised by tissue degeneration and accelerated aging (Gregg et al., 2011), 
including XP (Niedernhofer, 2008; Nouspikel, 2008).  
 
The Ercc1∆/- mice used in this chapter lack one ERCC1 allele, and produce a 
truncated form of the protein with reduced activity from the other allele. The 
Ercc1- and Ercc1∆ alleles were first generated in 1997 by Weeda and colleagues 
(Weeda et al., 1997). Ercc1∆/- mice have a prolonged life span and less severe 
degenerative phenotype than Ercc1-/- mice, due to the low level of residual 
ERCC1-XPF activity (Gregg et al., 2011). However, compared to wild-type 
littermates the Ercc1∆/- mice have reduced body weight, a shortened life span of 
24-30 weeks and develop progressive motor abnormalities including tremors 
and ataxia (de Waard et al., 2010; Gregg et al., 2011). 
 
I have used Ercc1∆/- mice to investigate the consequences of deficient DNA 
repair at the NMJ, using immunohistochemistry and confocal microscopy to 
study NMJ morphology in Ercc1∆/- mice at different ages.  
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5.2 Materials and methods 
 
5.2.1 Mice 
Mice were maintained in breeding colonies in animal care facilities in The 
Erasmus Medical Center, The Netherlands. All genotyping and basic dissection 
was performed in this location, and tissue was then shipped to Edinburgh for 
further dissection and analysis. Ercc1∆/- mice were obtained by crossing Ercc1-/+ 
with Ercc1∆/+ mice of C57Bl/6J and FVB backgrounds to yield Ercc1∆/- mice with 
C57Bl6J/FVB hybrid background. Wild-type C57Bl/6J mice maintained in 
breeding colonies at the University of Edinburgh were used as controls. 
 
5.2.2 NMJ Immunohistochemistry 
See general materials and methods, section 2.3. 
 
5.2.3 Microscopy 
See general materials and methods, section 2.4.  
 
5.2.4 Quantification of NMJs 
See general materials and methods, section 2.5. A minimum of 100 randomly 
selected endplates were categorized as being fully innervated (i.e. normal: 
neurofilament staining from a single incoming axon overlying the entire 
endplate), partially innervated, vacant (no neurofilament overlying the 
endplate), or poly-innervated (more than one axon converging on an individual 
endplate). 
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5.2.5 Statistical analysis 
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5.3 Results 
 
5.3.1 NMJ pathology in Ercc1∆/- mice 
Synapses are known to be early pathological targets in many diseases, and thus 
in diseases affecting lower motor neurons the NMJ is often vulnerable (Murray 
et al 2010). Motor neurons are thought to be affected by DNA damage in Ercc1∆/- 
mice (de Waard et al., 2010), so I therefore analysed the integrity of NMJs in the 
lumbrical muscles of these mice. Analysis was carried out at three time points – 
4 weeks, 8 weeks and 16 weeks of age. Ercc1∆/- mice have previously been 
shown to develop clasping of hind-limbs when lifted by their tails and tremors 
between 4 and 8 weeks (de Waard et al., 2010). By 16 weeks mice have 
developed severe locomotor deficits. Ercc1∆/- mice have a life span of 24-30 
weeks (de Waard et al., 2010). 
 
Qualitative assessment of muscles from a 16 week-old Ercc1∆/- mouse revealed 
many abnormalities at the NMJ (Fig. 5.1). By this age endplates in wild-type 
mice are fully occupied by an overlying nerve terminal and innervated by a 
single incoming axon collateral (mono-innervated). In contrast in the Ercc1∆/- 
mouse I found partial and vacant endplates within the same field of view as 
normal fully occupied endplates (Fig. 5.1A). Other endplates in the Ercc1∆/- 
mouse were poly-innervated (Fig. 5.1B). This morphology is only seen in wild-
type mice under two weeks of age, before developmental synapse elimination 
prunes all excess inputs back leaving NMJs in their adult mono-innervated state.  
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Analysis of the motor nerve terminals also revealed neurofilament 
accumulation, which does not occur at healthy NMJs (Fig. 5.1A). Incoming 
axons also showed abnormal neurofilament distribution, with some blebbing, 
and some very thin sections in the pre-terminal axon (Fig. 5.1D). One of the 
muscles examined had large amounts of abnormal and excessive axon 
branching across its entirety (Fig. 5.1C).  
 
Quantifying NMJ morphology in lumbrical muscles from Ercc1∆/- mice 
compared to wild-type controls at 4 weeks, 8 weeks and 16 weeks of age 
confirmed that these mice had high levels of pathology at the NMJ, manifesting 
in a variety of ways, which increased with age. Across the three time points 
there was a progressive and significant reduction in the percentage of normal 
mono-innervated and fully occupied endplates in the Ercc1∆/- mice (Fig. 5.2A). 
This corresponded with a significant increase in the levels of partially occupied 
endplates at 8 and 16 weeks of age (Fig. 5.2B) and an increase the percentage of 
vacant endplates across the time points studied (Fig. 5.2C). Levels of poly-
innervation were also significantly increased in the Ercc1∆/- mice (Fig. 5.3). 
 
 




Figure 5.1 – NMJ abnormalities in 16 week-old Ercc1∆/- mice. Confocal 
micrographs of NMJs in the lumbrical muscles of Ercc1∆/- mice show a range of 
abnormalities. A:  Whilst some endplates were still fully occupied and mono-
innervated (i.e. normal; white arrow) others in the same field of view were 
vacant (pink arrow) or partially occupied with the overlying nerve terminal 
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appearing to retract (pink arrowhead). Other NMJs had large accumulations of 
neurofilament in their pre-terminal axons (white arrowhead). B: Confocal 
micrograph showing a range of mono-innervated and poly-innervated (i.e. more 
than one incoming axon collateral) NMJs. The white arrows indicate normal (i.e. 
mono-innervated) NMJs whereas the blue arrows show poly-innervated NMJs. 
C: Confocal micrograph showing large amounts of abnormal and excessive axon 
branching in an Ercc1∆/- lumbrical muscle. D: Confocal micrograph showing 
abnormal neurofilament distribution in distal axon branches in a lumbrical 
muscle from an Ercc1∆/- mouse. The incoming axon is very thin (yellow arrow), 
but also contains regions of neurofilament accumulation (blue arrow). Scale bars 








Figure 5.2 - Quantification of NMJ abnormalities in Ercc1∆/- mice compared to 
wild-type controls at 4, 8 and 16 weeks of age. A: Bar chart (mean±SEM) 
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showing significant reduction in the percentage of fully occupied endplates in 
lumbrical muscles of Ercc1∆/- mice at 4, 8 and 16-weeks of age (4 weeks P<0.05, 8 
weeks P<0.01, 16 weeks P<0.001; Kruskal-Wallis test with Dunn’s post-hoc test). 
B: Bar chart (mean±SEM) showing significant increase in the percentage of 
partially occupied endplates in lumbrical muscles of Ercc1∆/- mice at 8 and 16-
weeks of age (4 weeks P>0.05, 8 weeks P<0.05, 16 weeks P<0.01; Kruskal-Wallis 
test with Dunn’s post-hoc test). C: Bar chart (mean±SEM) showing increase in 
the percentage of vacant endplates in lumbrical muscles of Ercc1∆/- mice (4 
weeks and 8 weeks P>0.05, 16 weeks P<0.01; Kruskal-Wallis test with Dunn’s 
post-hoc test; 4 weeks wild-type N=25 Ercc1∆/- N=16, 8 weeks wild-type N=6 
Ercc1∆/- N=10 , 16 weeks wild-type N=12 Ercc1∆/- N=16). 






Figure 5.3 – Quantification of levels of poly-innervation in 4-16 week-old 
Ercc1∆/- mice compared to wild-type controls. Bar chart (mean±SEM) showing 
significantly increased levels of poly-innervation in the lumbrical muscles of 
Ercc1∆/- mice compared to wild-type controls at 4, 8 and 16-weeks of age (4 and 
8 weeks P<0.05, 16 weeks P<0.001; Kruskal-Wallis test with Dunn’s post-hoc 
test; 4 weeks wild-type N=25 Ercc1∆/- N=16 , 8 weeks wild-type N=6 Ercc1∆/- 
N=10 , 16 weeks wild-type N=12 Ercc1∆/- N=16). 
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5.4 Discussion 
In this chapter I have shown that Ercc1∆/- mice develop age-dependant NMJ 
pathology in motor neurons, with morphological abnormalities such as 
neurofilament accumulation, abnormal and excessive axon branching and poly-
innervation of some endplates.  
 
Neurofilament accumulation is a common feature of neurodegenerative disease, 
and is seen in SMA, ALS, and Alzheimer’s disease (Murray et al., 2008a; 
Rouleau et al., 1996; Sternberger et al., 1985). The major function of 
neurofilaments is to provide mechanical support to axons, and accumulations of 
neurofilament are thought to disrupt the cytoskeleton and impair axonal 
transport (de Waard et al., 2010; Zhang et al., 1997). 
 
Poly-innervation of motor endplates is only seen in the healthy nervous system 
during development; in mice all endplates have usually reached the adult, 
mono-innervated state by two weeks of age (Keller-Peck et al., 2001). However, 
poly-innervation of adult endplates is seen in axons undergoing compensatory 
reinnervation following degeneration, for example in diseases such as ALS 
(Schaefer et al., 2005). The increase in the levels of poly-innervation in the 
Ercc1∆/- mice increases with age and coincides with increasing denervation of 
endplates, suggesting that some axons may be attempting to reinnervate 
vacated endplates, in an attempt to prolong muscle function. 
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The time course of neurodegeneration at the NMJ in the Ercc1∆/- mice correlates 
with the loss of motor neurons and an increase in motor abnormalities in these 
mice with age (de Waard et al., 2010). At 8 weeks of age Ercc1∆/- mice have 
tremors and show clasping of the hind limbs when lifted by the tail. By 16 weeks 
they have severe locomotor deficits and are unable to maintain balance (de 
Waard et al., 2010). This time point coincides with a 30% decrease in the number 
of fully innervated NMJs, which could account for the motor abnormalities 
these mice exhibit.  
 
As ERCC1 is involved in several different DNA repair pathways (NER, double 
strand break repair and interstrand crosslink repair) it is not clear which 
pathway or combination of pathways and which type of DNA lesion causes the 
neurodegeneration in Ercc1∆/- mice. Studies have shown that patients 
specifically deficient in the NER pathway, such as people suffering from XP, 
develop neuronal degeneration, indicating that the NER pathway is sufficient to 
cause degeneration on its own (Kraemer et al., 2007). However, a strain of mice 
which are completely without a NER pathway, whilst developing several cancer 
phenotypes, have not been reported to show any evidence of neurodegeneration 
(Melis et al., 2008), suggesting that NER acting in conjunction with other repair 
pathways may be responsible for the NMJ pathology seen in Ercc1∆/- mice. 
 
Build up of DNA damage due to deficiencies in DNA repair pathways has been 
linked to ALS (Bradley and Krasin, 1982; Coppedè et al., 2010), but at present 
there is no clear evidence that DNA repair genes are a causative factor in forms 
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of MND. One exception to this is the gene senataxin, mutations in which are 
linked to a rare autosomal dominant form of juvenile ALS (Chen et al., 2004). 
Senataxin is a DNA/RNA helicase, which has a role in the DNA damage 
response (specifically in double-strand repair), defending against oxidative 
stress (Suraweera et al., 2007). An early pathological event in ALS is the 
denervation of motor endplates (Fischer et al., 2004), as seen in the DNA repair 
deficient Ercc1∆/- mice. However, it is still unclear how DNA damage and motor 
neuron degeneration are linked.  
 
The data presented in this chapter is compatible with the model that a build up 
of DNA damage affects motor neurons in Ercc1∆/- mice, and indicates that DNA 
repair pathways involving ERCC1 are necessary for the maintenance of a 
healthy neuromuscular system. Further work is now needed in order to 
determine the mechanisms underlying the link between DNA repair and 
neurons.  
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Chapter 6 – General Discussion 
 
6.1 Overview of results 
The overall aim of this thesis was to examine the influence that expression of 
three distinct genes and their respective protein products – YFP, APOE and 
ERCC1 – on the health and stability of the PNS. Here I have shown that 
experimental manipulation of all three of these genes resulted in distinct effects 
on the PNS in vivo. 
 
YFP has been used as a reporter protein in the nervous system ever since the 
thy1-YFP mice were first generated in 2000 (Feng et al., 2000) and has previously 
reported to be inert (Feng et al., 2000; Ikawa et al., 1998; Lichtman and Sanes, 
2003; Okabe et al., 1997). Here I have shown that YFP protein expressed in 
neurons is not inert, but causes an up-regulation of cell stress responses 
specifically in YFP-expressing cells, subtly alters the morphology of axons and 
NMJs in healthy adult mice, and has diverse and unpredictable effects on 
different types of motor neuron degeneration.  
 
My studies on APOE have shown that alterations between the isoforms of apoE 
protein have consequences for both the regenerative capacity of the PNS in vivo 
and the proteome of peripheral nerves even in normal, healthy adult tissue. 
Presence of the human apoE4 isoform in mice selectively delays peripheral 
nerve regeneration and neuromuscular reinnervation, in the absence of any 
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effect on normal form or function, or on the rate of Wallerian degeneration 
following nerve crush injury. Proteomics experiments revealed alterations to the 
proteome of peripheral nerve in apoE4 mice, with changes in proteins associated 
with cellular outgrowth and regeneration, and integrity of the BNB. 
 
Mutations to ERCC1 are known to affect DNA repair pathways. Here I have 
shown that a loss of Ercc1 affects the PNS, causing a range of abnormalities at 
the NMJ that increase with age, including loss of neuromuscular connectivity, 
poly-innervation and neurofilament accumulation.  
 
6.2 Experimental manipulation of the PNS 
The finding that YFP is not inert highlights an important requirement for 
researchers to be aware of how manipulating the PNS can have unpredictable 
effects on the system. Earlier studies considered the possibility that YFP could 
be affecting neurons, but the parameters checked (life span of thy1-YFP mice 
and gross morphology of neurons) were unaltered, leading to the labeling of 
YFP as inert (Feng et al., 2000).  
 
Reporter proteins have been used both in vivo and in vitro for many years. Along 
with XFPs, other commonly used reporter proteins include β-galactosidase from 
Escherichia coli and firefly luciferase (Spergel et al., 2001). β-galactosidase has 
previously been reported to have toxic effects when expressed in vitro in 
primary cortical neurons, inducing apoptosis in these cells (Detrait et al., 2002). 
The effects of these two reporter proteins alone highlights the necessity of 
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performing appropriate controls in order to ensure that any responses recorded 
in a study are occurring as a result of experimental intervention, and not as a 
consequence of prior genetic manipulation of an organism. 
 
6.3 Clinical implications 
The finding that apoE genotype is a significant determinant of the success of 
nerve regeneration in vivo has implications for recovery from nerve injury in 
patients, and potentially for neurodegenerative diseases such as MND. 
Approximately 27% of the population is thought to carry at least one apoE4 
allele (Utermann et al., 1980). It is possible that for apoE4 carriers nerve 
regeneration would be slower than in others without the apoE4 allele, and 
recovery following peripheral nerve injury or rate of decline in 
neurodegenerative disease would be correspondingly worse. Therefore 
knowing a patient’s APOE genotype would allow clinicians to give a more 
accurate prognosis. 
 
Similarly, the finding that mutations in genes contributing to DNA repair 
pathways (ERCC1) can lead to significant pathology of motor neurons suggests 
that further studies are now required to examine whether mutations in other 
genes contributing to DNA repair pathways play a significant role in human 
MND. The ever-increasing speed of development of genomics technologies is 
likely to assist in such screens. 
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By pinpointing specific genes affecting the PNS, such as APOE and ERCC1, the 
likelihood of one day being able to design patient-specific therapeutics to give 
the best possible chance of recovery becomes more possible.  
 
6.4 Conclusion 
The work described in this thesis highlights the effects that three separate 
genetic factors can have on the form and function of the PNS in vivo.  As more 
genes affecting the PNS are identified and the molecular mechanisms 
underlying changes such as isoform specific regulation of the nervous system 
are unravelled, our knowledge of how the PNS functions will become clearer. 
Hopefully this study will be of benefit to future work on the genetic factors 
influencing the PNS in health and disease.  
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8 - Appendices 
 
Appendix 8.1 - iTRAQ proteomics methodology 
 
All proteomics experiments were performed at the Keele University Mass 
Spectrometry and Proteomics Facility, Wolfson Centre for Inherited 
Neuromuscular Disease, Oswestry. The following proteomics methodology is 
from Comley et al., 2011; 
 
“Reduction, alkylation and digestion steps were performed using the reagents 
and according to the recommendations in the iTRAQ labelling kit (Applied 
Biosystems). The extracts were diluted with 50mM TEAB so that the urea 
concentration was less than 1M, before the addition of trypsin and overnight 
incubation at 37°C. The digests were then dried down in a vacuum centrifuge 
and iTRAQ labelling was carried out according to the instructions in the iTRAQ 
labelling kit. The iTRAQ tags were assigned to samples as follows: 115-ApoE3 
and 117-ApoE4. Each tag was incubated with 85µg of protein (as determined by 
a Bradford protein assay). 
 
iTRAQ-labelled peptides were pooled and made up to a total volume of 2.4mls 
in SCX buffer A (10mM phosphate, pH3 in 20% acetonitrile (Romil, UK)). The 
pooled peptides (2.4mls) were then separated by strong cation-exchange 
chromatography (SCX) using a polysulfoethyl A column, 300A, 5uM (PolyLC)) 
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at a flow rate of 400ul/minute. Following sample injection, the column was 
washed with SCX buffer A until the baseline returned. The gradient was run as 
follows: 0-50% SCX buffer B (10mM phosphate, 1M NaCl, pH3 in 20% 
acetonitrile) over 25 minutes followed by a ramp up from 50% to 100% SCX 
buffer B over 5 minutes. The column was then washed in 100% SCX buffer B for 
5 minutes before equilibrating for 10 minutes with SCX buffer A. Fractions were 
collected (400ul) during the elution period and dried down completely in a 
vacuum centrifuge. 
 
The iTRAQ tryptic peptide fractions were each resuspended in 30µl of RP buffer 
A (2% acetonitrile, 0.05% TFA in water (Sigma Chromasolv plus). Prior to mass 
spectrometry analysis, fractions were first separated by liquid chromatography 
(Dionex Ultimate 3000) on a Pepmap C18 column, 200µm x 15cm (LC Packings) 
at a flow rate of 3µl/minute. Fractions were injected by full-loop injection (20µl) 
and the order of loading was randomized to minimise effects from carry-over. 
The eluants used were: A. 0.05% TFA in 2% acetonitrile in water and B. 0.05% 
TFA in 90% acetonitrile in water. The gradient was run as follows: 10 minutes 
isocratic pre-run at 100% A, followed by a linear gradient from 0-30% B over 100 
minutes, followed by another linear gradient from 30%-60% over 35minutes. 
The column was then washed in 100% B for a further 10 minutes, before a final 
equilibration step in 100% A for 10 minutes. During the elution gradient, sample 
was spotted at 10 second intervals using a Probot (LC Packings) with α-cyano-4-
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hydroxycinnamic acid (CHCA) at 3mg/ml (70% MeCN, 0.1% TFA) at a flow 
rate of 1.2µl/min. 
 
Both MS and MS/MS analysis was performed on the fractionated peptides 
using an Applied Biosystems 4800 MALDI TOF/TOF mass spectrometer. The 
mass spectrometer was operated under control of 4000 Series Explorer v3.5.2 
software (Applied Biosystems). A total of 1000 shots per MS spectrum (no stop 
conditions) and 2500 shots per MS/MS spectrum (no stop conditions) were 
acquired. The following MS/MS acquisition settings were used: 2KV operating 
mode with CID on and precursor mass window resolution set to 300.00 
(FWHM). Peak lists of MS and MS/MS spectra were generated using 4000 Series 
Explorer v3.5.2 software and the following parameters were used after selective 
labelling of monoisotopic mass peaks: MS peak lists: S/N threshold 10, Savitzky 
Golay smoothing (3 points across peak (FWHM)), no baseline correction, 
MS/MS peak lists: S/N threshold 14; smoothing algorithm: Savitzky Golay, 
smoothing (7 points across peak (FWHM)). 
 
An automated database search was run using GPS Explorer v3.6 (Applied 
Biosystems). MASCOT was used as the search engine to search the NCBI non-
redundant database (version 10/11/2009) using the following search 
parameters: precursor ion mass tolerance of 100ppm, MS/MS fragment ion 
mass tolerance of 0.3Da and iTRAQ fragment ion mass tolerance of 0.2Da. The 
enzyme was specified as trypsin with 1 missed cleavage permitted, oxidation of 
methionine residues were allowed as variable modifications and N-term 
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(iTRAQ), lysine (iTRAQ) and MMTS modification of cysteine residues were set 
as fixed modifications and the taxonomy was selected as Mus. The identification 
criterion was at least 2 unique peptides by MS/MS with the most stringent 
search settings in order to yield the most reliable data for iTRAQ quantification 
(peptide rank 1 and total ion score confidence intervals of at least 95%).  
 
Peptides were reported as identified iTRAQ peptides only if they met the 
following criteria: iTRAQ ratio of greater than 0, all N-terminal and lysine 
residues were labelled and did not include tyrosine_iTRAQ modification. 
Quantification of the iTRAQ peptides was performed by applying the following 
formula: corrected cluster area of fragment / corrected cluster area of reference 
(i.e. 117 (ApoE4)/115 (ApoE3)). Following correction using kit-specific-iTRAQ 
correction factors, iTRAQ ratios were normalized to the median ratio using the 
following formula: iTRAQ Ratio = Ratio / (median iTRAQ Ratio of all found 
pairs). Both correction and normalization was performed using GPS Explorer 
software v3.6.” 
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Appendix 8.3 – Conference abstracts 
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the CNS and Periphery, Chicago, USA (Talk and poster) 
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system.” 
 
2011 – Edinburgh Neuroscience Day, UK (Poster) 
“Induction of Cell Stress in Neurons from Transgenic Mice Expressing Yellow 
Fluorescent Protein: Implications for Neurodegeneration Research.” 
 
2010 – 7th FENS Forum of European Neuroscience, Amsterdam, The 
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2010 – Anatomical Society Winter Conference, Oxford, UK (Poster) 
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